

Index

Note: page numbers in *italics* refer to figures and page numbers in **bold** refer to tables.

- AAMI. *See* Association for the Advancement of Medical Instrumentation (AAMI)
- AASK trials. *See* African American Study of Kidney Disease and Hypertension (AASK)
- ABCD study. *See* Appropriate Blood Pressure Control in Diabetes (ABCD) study
- abdominal pain, with peritoneal dialysis, 510
- abetimus sodium (LJP 394), for lupus nephritis, **249**, 250
- access-related infections from hemodialysis prevention
 - antibacterial lumen locks, 444–445
 - cannula characteristics, 444
 - exit site cleaning/skin care, 444
 - insertion, 444
 - treatment, 445–447
- acetate-free biofiltration (AFB), 410
- acetazolamide, 128, 615, 643, 648
- acetylcysteine, 227, 484
- acid-base disorders
 - acid-base normal physiology, 611–612
 - diagnosis, 612
 - metabolic acidosis
 - contributory factors/consequences, 432
 - correction of, 432–433
 - description, 612–613
 - redistribution hyperkalemia from, 634
 - treatment, 613–615
 - in CKD, 614
 - lactic acidosis, 613–614
 - RTA type IV, 614
 - metabolic alkalosis, 615, **615**
 - acid-base regulation during pregnancy, 300
- Acute Dialysis Quality Initiative (ADQI), 72, 141
- acute fatty liver, during pregnancy, 303, 304
- acute glomerulonephritis, 81, 281
- acute interstitial nephritis (AIN), 122–126
 - causes of, 122, **123–124**, 125, 126
 - clinical features, 122–123
 - course/treatment of, 125–126
 - definition/etiology/pathogenesis, 122
 - diagnosis, 123, 124
 - laboratory findings, 123, 125
- acute kidney injury (AKI). *See also* acute tubular necrosis (ATN)
 - biomarkers (potential) of, **76**
 - epidemiology of, 72–74
 - etiologies of
 - acute interstitial nephritis, 122–126
 - atheroembolic renal disease, 132–134
 - crystalline nephropathies, 127–128
 - ethylene glycol poisoning, 132
 - multiple myeloma associated with AKI, 126–127
 - renal artery/vein thromboses, 134
 - tumor lysis syndrome, 128–132
 - mortality outcomes of, 75
 - outcomes in, 74–75
 - renal replacement therapy in, 137–144
 - RIFLE criteria for defining, 72, 74
 - limitations of, 75
 - secondary to bisphosphonate therapy, 127
- Acute Kidney Injury Network (AKIN), 72
- acute renal failure (ARF)
 - acidosis/lactic acidosis association with, 614
 - CIN causation, 110
 - from COX-2 cyclooxygenases, 288
 - defined, 71, 73–74
 - in elderly patients, 31
 - HSP nephritis and, 808
 - hyperphosphatemia and, 360
 - ICD-9 codes for, 74
 - RIFLE criteria for, 72
- Acute Renal Failure Trial Network (ATN) study, 141
- acute tubular necrosis (ATN)
 - ACEi/ARBs precipitation of, 80
 - causes of, 97
 - from COX-2 cyclooxygenases, 288
 - diagnosis, 97
 - outcomes, 98
 - pathophysiology, 97–98, 98
 - pharmacologic therapy (once established), 104–106
 - dopamine, 105
 - fenoldopam, 105
 - loop diuretics, 105
 - natriuretic peptides, 105–106
 - during pregnancy, 304
 - preventive strategies, 98–104
 - aminoglycosides, 98–99
 - amphotericin B, 99
 - lipid-based formulations, 100
 - by saline (volume expansion), 99–100
 - dopamine, 101–102
 - fenoldopam, 102–103
 - from ischemic/postoperative ATN, 101
 - loop diuretics, 101
 - mechanical ventilation modulation, 104
 - N-acetylcysteine (NAC), 103–104
 - from rhabdomyolysis, 100
 - with mannitol bicarbonate, 100–101
 - with saline resuscitation, 100
- acute tubulo-interstitial nephritis, 288–289, 294
- acyclovir, 127, 260
 - as cause of crystalline nephropathies, 127
 - for cytomegalovirus, 707
 - for reduction of varicella transmission rate, 768
- adefovir, 259, 260
- adefovir dipivoxil, for HBV-associated MPGN, 266
- ADEMEX peritoneal dialysis trial, 479, 480
- adrenocorticotrophic hormone (ACTH)
 - for idiopathic membranous nephropathy, 166–167
 - for SRNS (1950s–1980s), 794
- adult Immunoglobulin A nephropathy (IgAN)
 - comorbidities
 - isolated microscopic hematuria and proteinuria, 175
 - with nephrotic syndrome, 176
 - with rapidly declining GFR, 175–176
 - with recurrent microscopic hematuria, 174–175
 - with slowly progressing renal impairment, 176–177
 - COOPERATE study, 174
 - evidence, 173–174
 - immunosuppressive treatments
 - corticosteroids, 177
 - cyclophosphamide with/without azathioprine, 177
 - fish oil, 179, **179**
 - MMF and mizoribine, 179
 - methods, 172–173
 - natural history, 170–171
 - prognostic factors, 171–172
 - recommendations, 173

Index

- Adult Treatment Panel III (ATP III), 570
 Advisory Committee on Immunization Practices, 456
 African Americans
 diabetes risks, 49
 ESRD rates, vs. White people, 9, 63
 family history influence, 48
 and HIV-associated collapsing glomerulopathy, 253–254
 hypertension in, 220, 347
 living donor considerations, 548–549
 prevalence of nephrotic FSGS, 152
 PVAN risks, 278
 risks for microalbuminuria, 551
 African American Study of Kidney Disease and Hypertension (AASK), 32, 49, 64, 209, 216, 239, 417
 Afro-Caribbean cultures and diabetic nephropathy, 233
 AIN. *See* acute interstitial nephritis (AIN)
 AIPRI study, 34
 albuminuria. *See also* African American Study of Kidney Disease and Hypertension; HOPE study; macroalbuminuria; microalbuminuria
 in diabetic nephropathy, 217, 232
 HCV infection and, 272, 273
 in hypertension, 208, 209, 217–219
 in hypertensive renal disease s, 204
 in living donors, 551
 lowering of via ACEi/ARBs, 64
 as marker for diabetic/nondiabetic kidney disease, 217
 in membranoproliferative glomerulonephritis, 189
 predictive for CV events/diabetes, 31, 232, 234, 578
 quantification of, 30
 in type 1/type 2 diabetes, 232
 aldosterone antagonists, 219, 238, 317, 614, 673
 Alemtuzumab (Campath-1H) monoclonal antibody, 577
 ALERT study, 336, 569–570, 601
 alkylating agents
 for FSGS, 153
 for MCD, 151
 for pediatric SRNS, 792, 794
 ALLHAT study (of patients with CKD), 218, 220, 316, 351
 allograft rejection, 561, 563
 predictive usefulness of, 563
 UTI as risk factor, 566
 allopurinol
 for hypouricemic therapy, 131
 for kidney stone prevention, 646
 alpha interferon (IFN- α)
 for HBV-associated MPGN, 265–266
 in HCV-associated MPGN, 275
 Alport syndrome, 540–541
 aluminum salts, for hyperphosphatemia, 365
 ambulatory blood pressure monitoring (ABPM), 201–202, 669–670
 American College of Rheumatology, 244
 American Society for Bone and Mineral Research, 355
 American Transplant Society survey, 567
 amino acid dialysates, 435, 504–506, 505
 amino acid supplements, 435, 659
 aminoglycoside
 hepatorenal syndrome and, 90
 prevention of ATN from, 98–99
 reasons for avoidance of, 525
 safety issues, 99
 for treatment of peritonitis in PD, 483–484
 amlodipine
 in diabetes mellitus, 237, 238
 for hypertension, 34, 209, 316, 317, 346, 351
 in children, 670
 vs. metoprolol/ramipril, 351
 vs. ramipril, 351
 for RAS blockade in IgAN, 174
 vs. ramipril, 220
 amphotericin B
 causative for hypokalemia, 638
 prevention of ATN from, 99–100
 by saline (volume expansion), prevention of ATN from, 99–100
 ampicillin
 as cause of AIN, 123
 as cause of crystalline nephropathies, 127
 in peritonitis, 730
 anatomic evaluation, of living donors, 553
 anemia in chronic kidney disease (CKD). *See also* pediatric anemia
 ESA therapy, 327–328, 328, 329
 evaluation, 323–324
 hemoglobin targets, 324–327
 blood pressure, 327
 dialysis adequacy/change in GFR, 327
 hemodialysis access, 327
 left ventricle size, 327
 mortality/cardiovascular events, 324, 327
 quality of life, 327
 transfusions, 327
 iron therapy
 formulation comparison, 329
 modes of administration, 329–330
 status markers, 328–329
 angioplasty
 N-acetylcysteine and, 115
 for ostial stenoses, 226
 in pediatric patients, 743
 in renovascular disease, 223, 224, 225, 226–227
 in vascular access thrombosis, 460, 461
 angiotensin converting enzyme inhibitors (ACEi), 34, 35.
 See also Evaluation of Losartan in the Elderly (ELITE) study; lisinopril; ramipril
 for BP in type 2 diabetes, 231
 for cardiorenal syndrome, 84
 for chronic allograft nephropathy, 604
 for cystinosis, 819
 evaluation for MPGN, 188, 189
 in HCV-associated MPGN, 275
 for HIV-associated glomerulonephritis, 257–258
 with HAART, 260
 for hypertension in CKD, 218, 346
 for hypertensive patients in CAPD, 483
 for IgAN, 173
 ineffectiveness for proteinuria, 160
 for lowering of albuminuria, 64
 for lupus nephritis, 246
 for membranous nephropathy, 158, 166
 for microalbuminuria, 240
 for pediatric hypertension, 670, 672
 for pediatric SRNS, 797
 precipitation of ATN, 80
 RAS suppression from, 673
 for renal artery stenosis, 223
 for slowing progression of disease, 313, 314, 316
 with ARBs, 316
 angiotensin receptor blockers (ARBs), 34, 35. *See also* Evaluation of Losartan in the Elderly (ELITE) study; irbesartan
 for cardiorenal syndrome, 84
 for chronic allograft nephropathy, 604
 in HCV-associated MPGN, 275
 for HIV-associated glomerulonephritis with HAART, 260
 for hypertension in CKD, 218, 346
 for hypertensive patients in CAPD, 483
 for IgAN, 173–174
 for lowering of albuminuria, 64
 for lupus nephritis, 246
 for membranous nephropathy, 166
 for pediatric hypertension, 670
 precipitation of ATN, 80
 for slowing progression of disease, 314, 316
 with ACEi, 316
 antibacterial lumen locks, 444–445
 antibiotics
 as antimicrobial intervention, 509
 as cause of AIN, 122
 as cause of kidney stones, 643, 647
 for exit site/tunnel infection, 511
 for hemodialysis infections, 442, 445
 for pediatric patients
 intravenous administration, 731, 747
 prophylactic use, 749, 767, 768
 for peritonitis, 511–512, 520, 727
 with intraperitoneal immunoglobulin, 527
 anti-CD25 antibodies, 577, 586
 clinical trials, 578–579
 vs. other monoclonal/polyclonal antibodies, 581
 vs. placebo, for graft rejection, 580
 anticoagulation
 citrate anticoagulation, 143
 use of in RRT for AKI, 142–143
 antidiuretic hormone (ADH) levels
 in hyponatremia, 618, 620, 629, 630
 in primary nocturnal enuresis, 753
 release of, in decreased renal perfusion, 80
 antiretroviral therapy. *See also* highly active antiretroviral therapy (HAART)
 for HIV-associated glomerulonephritis, 258
 indirect effects in promotion of chronic kidney disease, 259
 renal injuries induced by, 259
 antiviral therapy
 in BK virus infection, 604
 HAART and, 257
 in HBV infection, 267
 in HCV-associated MPGN, 275
 in PVAN, 280, 301
 ANZDATA. *See* Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry
 APD. *See* automated peritoneal dialysis (APD)
 apparent mineralocorticoid excess, 202
 Appropriate Blood Pressure Control in Diabetes (ABCD) study, 216, 239
 arachidonic acid metabolism pathway, 287

- arterial thromboembolism (ATE), 160
- arteriovenous fistula (AVF)
- in essential hypertension, 202
 - evidence for in vascular access planning, 395–396
 - failure prevention, pharmacological approaches, 463–464
 - for pediatric hemodialysis, 738
 - in pediatric hemodialysis, 738
 - thrombosis reduction rate with Qa surveillance, 461
 - for vascular access for hemodialysis, 460
 - in vascular access infections, 442
- arteriovenous graft (AVG), 442, 443
- failure prevention, pharmacological approaches, 463–464
 - Qa surveillance studies, 460–461
- Asian cultures
- diabetes/diabetic nephropathy, 220, 231, 233
 - HIV-associated glomerulonephritis, 258
 - IgA nephropathy in, 170
 - prevalence in albuminuria, 49
- aspirin
- for AVF/AVG failure, 463
 - with dipyridamole
 - for AVG, 463–464
 - for MPGN, 188, 190
 - low-dose
 - for CKD, 318
 - inhibition of platelet COX-1, 286
 - for preeclampsia prevention, 305, 306
 - for women with SLE, 302
- assessment of CKD progression
- albuminuria/proteinuria quantification, 30
 - GFR measurement, 29–30
 - renal resistance index, 30
- Assessment of Lescol in Renal Transplantation (ALERT) study, 568
- Association for the Advancement of Medical Instrumentation (AAMI), 455, 456
- atheroembolic renal disease, 132–134
- clinical features/lab findings, 132, 133
 - course and management, 132–134
 - definition, prevalence, pathogenesis, 132
- atorvastatin, 336, 338, 371
- atrial natriuretic peptides, 104, 105
- attendant hyperkalemia, 288
- AURORA statin comparison study, 336, 437–438
- Australia. *See also* Caring for Australians with Renal Impairment (CARI) guidelines; IDEAL study (of dialysis start time)
- ESRD survival rates, 232
 - incidence of ARF, 73
 - kidney transplant rates, 574
 - mortality in overweight patients, 474
 - nutritional guidelines in hemodialysis, 434
 - transplantation statistics, 574
 - varicella-zoster infection care for children, 768
- Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, 21, 500
- Australia and New Zealand Society of Nephrology, 511
- automated peritoneal dialysis (APD), 479
- azathioprine
- with corticosteroids vs. azathioprine, 592
 - with cyclophosphamide, for lupus nephritis, 247, 248
 - for pediatric steroid-resistant nephrotic syndrome, 792
- for PVAN, 280
- with warfarin, dipyridamole, steroids, for MPGN, 190
- bacterial infections related to dialysis, 453
- Enterobacter* bacteremia, 453
 - Serratia* bloodstream infections, 453
 - Staphylococcus aureus*, 442, 443, 445
 - Staphylococcus epidermidis*, 443
- Bartter syndrome, 615, 637
- basiliximab monoclonal antibody, 577
- benazepril, 174, 670
- Bence-Jones proteinuria, 127
- Bergamo Nephrologic Diabetes Complication Trial (BENEDICT) study, 34, 240
- Best Pharmaceuticals for Children trial, 670
- beta (β)-2 agonists and hyperkalemia, 636
- beta-blockers, 216, 238, 317, 351. *See also* metoprolol
- causative for increased serum lipids, 220
 - in MPGN, 814
 - for proteinuria, 219
 - for slowing GFR decline, 317
 - vs. calcium channel blockers, 275
 - vs. ndCCBs, 238
- bicarbonates. *See also* dialysate buffer; sodium bicarbonate
- clinical benefits, 503
 - for contrast-induced nephropathy, 112, 115
 - for CRRT, 143
 - for hyperkalemia treatment, 636
 - in hyperkalemia treatment, 431
 - in hypertension, 203
 - losses of, in metabolic acidosis, 432
 - low readings in renal tubular acidosis, 643, 646
 - as preferred buffer for HD/HDF, 411
 - resorption with glomeruli filtration, 612
- bioimpedance assay (BIA) in hemodialysis patients, 435
- BK virus (BKV), 277–282, 707
- in chronic allograft nephropathy, 601
 - treatment, 604
 - defined, 277
 - kinetic/half-life estimates, 278
 - in polyomavirus-associated nephropathy, 277–282
 - replication activation mechanics, 278, 279
 - screening for, 279, 280, 282
- bladder catheterization, 75, 155
- blood eosinophilia, 133, 227
- blood pressure. *See also* Appropriate Blood Pressure Control in Diabetes (ABCD) study; hypertension (HTN)
- control of in hemodialysis, 433
 - ESRD and, 347
 - goal in CKD/hypertension, 347
 - IgAN recommendations, 173
 - intensified control, in diabetic nephropathy, 238–239
 - progression of nephropathy and levels of, 346
 - regulation during pregnancy, 300
 - RENAAL study, 346
 - setting determinations
 - ambulatory monitoring, 201–202
 - clinics, 200–201
 - home monitoring, 201
 - other settings, 202
 - targeting of in hypertension, 172
 - targeting of in lupus nephritis, 246–247
- blood urea nitrogen (BUN), 137, 304, 339
- NCDS study, 424
 - in pediatric hemodialysis, 740–741
 - predialysis levels/calculations, 424
 - in pre-renal failure, 80
- body mass index (BMI)
- African Americans and, 9, 474
 - assessment for transplantation, 335, 658
 - assessment of in donors, 547
 - consideration in living donor evaluation, 554
 - elevated serum creatinine association, 49
 - ESRD risks and, 25
 - hypertension and, 204, 216
 - PD choice as RRT and, 474
 - predictive for hyponatremia, 620
 - proteinuria and, 26, 36
- brain natriuretic peptide (BNP), 84, 185
- Brescia-Cimino arteriovenous fistula, 395, 410
- British Columbia Renal Agency, 24
- British Hypertension Society, 219
- British Renal Association (BRA), 511
- B-type natriuretic peptides (BNP), 84
- cadmium (environmental nephrotoxin), 296–297
- calcimimetic therapy, 374–375
- calcineurin inhibitors (CNI), 592. *See also* cyclosporine A (CsA); tacrolimus
- for CAN prevention, 601, 603
 - with mTOR inhibitors, 603
 - in chronic allograft nephropathy, 601
 - hypertensinogenic contributions of, 669
 - for idiopathic nephrotic syndrome in children, 766
 - maintenance immunosuppression without, 594–597
 - for pediatric steroid-resistant nephrotic syndrome, 787–788
 - renal failure from chronic administration, 595, 599
- calcitriol. *See also* vitamin D
- impaired synthesis in renal osteodystrophy, 685
 - oral administration
 - for children/adolescents with CKD, 686
 - for improved bone metabolism in children, 688
 - vs. cholecalciferol, 358
 - vs. paricalcitol, 359
- calcium (Ca²⁺) gluconate chloride, 635
- calcium acetate/calcium carbonate for hyperphosphatemia, 367
- calcium-based phosphate binders, 367
- calcium channel blockers, 218. *See also* nondihydropyridine calcium channel blockers (NDHCCBs)
- beta-blockers vs., 275
 - for diabetic nephropathy, 238
 - evaluation for MPGN, 189
 - for hypertension, 209
 - uselessness against radiocontrast toxicity, 227
- calcium ethylenediaminetetraacetic acid (CaNa₂-EDTA) therapy, 295–296
- calcium renal stones, 643–644
- CaNa₂-EDTA therapy. *See* calcium ethylenediaminetetraacetic acid (CaNa₂-EDTA) therapy
- Canada, transplantation statistics, 574
- Canadian Organ Replacement Register, 21

Index

- Canadian Organ Replacement Register (CORR), 21, 405–406
- Canadian Society of Nephrology, 478
- cancer/cancer patients
- antibacterial lumen locks and, 444
 - as comorbid condition, 12
 - donor evaluation, **546**
 - evidence/recommendations, 538–539
 - increased urinary BKV replication, 277
 - obesity association, 554
 - screening strategies, **538**
 - treatment with IFN, 266
 - vitamin D hormone replacement, 356
- Candesartan and Lisinopril Microalbuminuria (CALM) study, 237
- Candida* spp., 447
- Can-It (Canadian-Italian) Impact Study, 394
- cannula characteristics (in dialysis), 444
- CAN. *See* chronic allograft nephropathy (CAN)
- CANUSA study (of death risk for incident PD patients), 404, 478
- CAPD. *See* continuous ambulatory peritoneal dialysis (CAPD)
- captopril, 649
- captopril scintigraphy, for renal artery screening, 224–226, **226**, 228
- cardiopulmonary bypass (CPB), 103–104
- cardiorenal syndrome, 234–235
- causes of, 83
 - treatment of, 83–84
 - ACEi/ARBs, 84
 - diuretics, 84
 - natriuretic peptides, 84
 - ultrafiltration, 84
- cardiovascular disease. *See also* angiotensin converting enzyme inhibitors (ACEi); angiotensin receptor blockers (ARBs); body mass index (BMI); Framingham Heart Study; hypertension; hypertension in chronic kidney disease (CKD)
- in children with CKD, 669, 670–672
 - prevention strategies, 672–673
 - as CKD risk factor, 46–47
 - coronary artery noninvasive screening, **536**
 - end point studies on lipid-lowering therapies
 - CKD stages (1–4), 336
 - transplantation, 336–337
 - CKD stage V: dialysis, 336
 - evidence/recommendations for transplantation, 535–537
 - GFR's association with, 43
 - impact of dyslipidemia
 - dialysis, 335
 - nephrotic syndrome, 335
 - therapy for lowering, 337–340
 - transplantation, 335–336
 - macro-/microalbuminuria as risk factors, 64
 - metabolic syndrome and, 234
 - type 2 diabetes and, 233
- cardiovascular disease and posttransplantation outcomes
- interventions for risk reduction
 - dyslipidemia, 568–569
 - immunosuppressive regimen choice, 569
 - recommendations, 569–570
 - performance of risk assessment strategies
 - FHS and nontraditional factors, 568, **568**
 - pretransplantation screening, 567–568
 - recommendations, 568
 - rationale for CVD risk assessment
 - clinical risk scores, 567
 - pretransplantation cardiac screening, 567
- Cardiovascular Health Study, 43, 46
- Caring for Australians with Renal Impairment (CARI) guidelines, 412, 511, 512, 525, 694
- cast nephropathy
- clinical features/lab findings, 126–127
 - course and treatment, 127
 - myeloma cast nephropathy, 127
- catheter use. *See also* Fluids and Catheter Treatment Trial (ARDS Network group)
- cuffed/uncuffed central venous (CVC), 460, 464, **464**, 739
 - dialysate leaks, 490
 - increased morbidity/mortality from, 392
 - for K⁺ repletion, 638
 - in pediatric hemodialysis, **742**
 - for pediatric peritoneal dialysis, 726–727
 - for peritoneal dialysis, 509, 510, 512
 - peritonitis from, 397, 511
 - prevention interventions, 522–523
 - problems related to, 491
 - for vascular access in dialysis, 392
 - cuffed/tunneled catheters, 396
 - femoral vein catheters, 396
 - infections related to, 442–443, **443**, 444
 - peritoneal catheters, 396–397
- Caucasians
- atheroembolic renal disease prevalence, 132
 - donor issues, 548, 550, 552
 - ESRD rates, vs. African Americans, 9, 63
 - family history influence, 48
 - hip fracture risks of ESRD patients, 375
 - HIV-associated glomerulonephritis in, 258
 - MN as cause of NS in, 158
 - risk of ESRD from HIV-associated nephropathy, 253
 - transplantation issues, 594, 708
- cefazolin, 483, **513**, **516**, **517**
- cefuroxime, 512, **513**, **516**, **517**
- celecoxib (COX-2), 286, 288, 289
- cellulose dialysis membranes, 410
- Centers for Disease Control (CDC)
- CKD epidemiology, 8
 - diagnostic criteria for HD catheter-related infections, 445
 - dialysis center control guidelines, **457**
 - dialysis center survey, 453
 - HAART and, 257
 - surveillance definition, 18
- Centers for Medicare & Medicaid Services (CMS), 26, 393, 447, 548
- central pontine myelinolysis, 618
- central venous catheters (CVCs), 443, 460, 638, **739**
- cerebral salt wasting, 620
- cerebral vascular disease, 537
- Child-Pugh scores, in HRS, 89, 93
- children. *See also* pediatric anemia; pediatric chronic kidney disease (CKD); pediatric daytime urinary incontinence; pediatric hemodialysis; pediatric hypertension/CVD in CKD; pediatric immunoglobulin A nephropathy (IgAN); pediatric kidney transplantation; pediatric nocturnal enuresis; pediatric peritoneal dialysis (PD); pediatric renal osteodystrophy; pediatric steroid-resistant nephrotic syndrome (SRNS); pediatric thrombosis; pediatric urinary tract infections (UTIs); pediatric vesicoureteric reflux
- diabetic ketoacidosis in, 614–615
 - effect of height on long-term outcome, 661
 - with HBV-associated glomerulonephritis, 264
 - phases of growth (sequential)
 - prenatal, 654
 - infant, 654
 - childhood phase, 654
 - dietary supplementation, **657–658**
 - EAA supplementation, **659**
 - puberty, 654
- children, benefits of interventions on nutrition/growth
- amino acids-containing PD solutions, 659, **660**
 - dialysis adequacy, 660, **661**
 - essential amino acid supplements, 659
 - intradialytic parenteral nutrition, 659–660, **660**
 - nasogastric/gastronomy feeds, 659
 - nutritional supplementation, **657–658**, 659, **659**
 - recombinant human growth hormone (rhGH), 661, **662**
 - steroid issues, 661, **663**, 670
 - table for all interventions, **663**
- children, prevalence/severity/natural history of growth disorders in kidney disease
- chronic kidney failure
 - childhood phase, 655
 - prenatal/infantile phases, 655
 - pubertal phases, 655
 - dialysis
 - childhood phase, 656
 - infantile phase, 655–656
 - pubertal phase, 656
 - final height (FH), 656, 661
 - posttransplantation
 - childhood phase, 656
 - infantile phase, 656
 - obesity, 656
 - pubertal phase, 656
 - steroid-sensitive nephrotic syndrome, 654–655
- chlorambucil, 151, 153
- chlorhexidine (topical antiseptic), 444
- chlorthalidone, 351
- Choices for Healthy Outcomes in Caring for End-State Renal Disease (CHOICE) study, 391, 393, 395, 396
- cholecalciferol, for CKD/ESRD, 357. *See also* vitamin D
- chronic allograft nephropathy (CAN)
- ALERT study, 601, 604
 - BK virus nephropathy, 601
 - clinical factors/progression of, 601
 - CNI nephrotoxicity, 601
 - CONVERT trial, 604
 - course/development of, 599–600
 - defined, 599
 - DIRECT study, 603
 - immunological injury
 - acute rejection episodes, 600

- antibody-mediated rejection, 600–601
- subclinical rejection, 600
- impact of, 604–605
- prevention/treatment of
 - BK virus infection, 604
 - immunosuppressive agents, 604
 - modalities of, **602**
 - primary, 602–603
 - secondary, 603–604
 - statins, 604
 - switch studies, 604
 - SYMPHONY study, 603
 - TRANCEPT observational study, 604
- chronic glomerulonephritis
- chronic proteinuric nephropathy and, 36
- effectiveness of ACEi for, 220
- MPGN association, 183
- organic solvent exposure and, 297
- during pregnancy, 302, 303
- chronic kidney disease (CKD). *See also* mineral and bone disorder (MBD) of CKD/ESRD; pediatric chronic kidney disease (CKD); renal damage, from hypertension
 - ACEi/ARBs for, 246
 - acidosis in, 614
 - anemia treatment in, 323–330
 - antiviral therapy promotion of, 259
 - blood pressure/hypertension goals, 347
 - characteristics of, 3
 - and CKD stages, complications of, 7–8
 - cost-effective analysis for screening
 - diabetic nephropathy, 51–52
 - nondiabetic nephropathy, 52
 - defined
 - functional abnormalities, 4
 - structural abnormalities, 3–4
 - due to diabetes mellitus, 209, 231
 - dyslipidemia in, 333–340
 - epidemiology (descriptive)
 - incidence trends, 11–12
 - race and CKD, 9–10
 - stage 1–4 prevalence, 7–8
 - stage 5 comorbidities, 12–13
 - stage 5 incidence/prevalence, 10–11
 - etiological/functional diagnoses for, 6
 - GFR decline in, 239
 - hemoglobin targets in, 324–327
 - high-risk populations/risk factors for, 46–51
 - cardiovascular disease, 46–48, **47**
 - diabetes, **47, 48**
 - elderly, 46
 - family history, **48, 48**
 - hypertension, **46, 47**
 - race/ethnicity, 48–49, **50**
 - stages 1–4 CKD, 49–51
 - HIV-1 infection and, 253, 260
 - hypertension in (*See* hypertension in chronic kidney disease (CKD))
 - mortality/ESRD risk associated with, 61–64
 - NKF staging definitions, 5
 - NSAIDs promotion of, 289
 - practice-based screening/quality management, 26–27
 - in pregnancy, 301
 - prevalence of, in U.S., **4**
- progression to, 150, 170
 - IgAN, 173
 - proteinuria, 231
 - stages of, prognostic importance of, 6, 7
 - types of, 219–220
- chronic kidney disease (CKD), growth disorders natural history
 - chronic kidney failure
 - childhood phase, 655
 - pubertal phases, 655
 - childhood phase, 656
 - infantile phase, 655–656
 - pubertal phase, 656
 - final height (FH), 656
 - posttransplantation
 - childhood phase, 656
 - infantile phase, 656
 - obesity, 656
 - pubertal phase, 656
 - steroid-sensitive nephrotic syndrome, 654–655
- chronic kidney disease (CKD), treatment strategies for delay/prevention
 - ACEi, 313, 316
 - aldosterone antagonists, 317
 - beta blockers, 317
 - blood pressure control, 31–33, 313, **314, 315**
 - correction of severe anemia, 318
 - dihydropyridine CCB avoidance, 316
 - diuretic therapy, 316–317
 - herbal therapy, avoidance of, 318
 - hyperphosphatemia/hyperparathyroidism control, 318
 - metabolic syndrome control, 317
 - NAHCO₃, 318
 - NDHCCB therapy, 317
 - NSAIDs avoidance, 318
 - obesity, 36
 - protein intake control, 37, 316
 - RAAS blockade, 35–36
 - reduction of proteinuria, 33–34
 - renin inhibition, 318
 - restriction of salt intake, 37, 316–317
 - smoking/smoking cessation, 36, 318
 - uric acid level control, 318
 - water intake control, 37
- chronic pyelonephritis, 303
- chronic thrombotic microangiopathies, 183
- cidofovir, 259, 280
- CIN. *See* contrast-induced nephropathy (CIN)
- ciprofloxacin, as cause of crystalline nephropathies, 127
- cirrhosis (of liver)
 - ARF and, 81, 83
 - HRS pathogenesis in, **89**
 - hyponatremia in, 621
- citrate for kidney stones, 646
- CKD-CVD complex (risk stratification of CKD/CVD risk), 218–220
 - dyslipidemia, 220
 - proteinuria, 219
 - race and ethnicity, 220
 - stages of CKD, 219
 - types of CKD, 219–220
- Clinical Modification of ICD-9 (ICD-9-CM), 5
- Clostridium difficile* in CKD/RRT populations, 442
- cloudy effluent, with peritoneal dialysis, 510
- coagulation abnormalities, evaluation in living donors, 546
- Cochrane Database review
 - of aminoglycoside-based treatment regimens, 99
 - antibiotic prophylaxis for UTI prevention, 566
 - antimicrobial agents, 512
 - comparison of HD, HE, HDF, AFB, 416
 - dialysis recommendations
 - PD vs. HD, 471, **472**
 - reuse issues, 456
 - low-dose aspirin/fish oil for AVG, 463
 - plasma-derived recombinant vaccines trial reviews, 456
 - statin efficacy in hemodialysis populations, 416
 - study of biocompatible membranes, 142
- Cochrane Renal Group, 177, **178**
- Cockcroft-Gault creatinine clearance equation, 4
 - as aid to dialysis start determination, 404
 - GFR association with, 208
 - limitations of, 58–59
 - in lupus nephritis, 244
 - performance analysis, **59**
 - during pregnancy, 301
- Collaborative Transplant Study (CTS), 594
- congenital adrenal hyperplasia, 202
- congestive heart failure (CHF)
 - hyponatremia in, 621
 - incidence in dialysis patients, 535
 - posttransplantation incidence and prognosis, **569**
 - septicemia and, 452
- Consolidated Standards of Reporting Trials (CONSORT), 703
- continuous ambulatory peritoneal dialysis (CAPD), 405, 426, 478
 - ACEi/ARBs for hypertensive patients, 483
 - dyslipidemia and, 334
 - increased exchanges in small solute clearance, 482
 - sodium removal during APD and, 493
 - survival benefits, 479
- continuous RRT (CRRT), 137, 138
 - for AKI, 137, 138
 - critically ill patient trials, 143
 - dialysate buffer for, 143–144
 - IHD vs., 139–140
 - lactate buffered vs. bicarbonate-buffered fluid in, **143**
- continuous venovenous hemofiltration (CVVH), 138, 140
- contrast-induced nephropathy (CIN)
 - ARF caused by, 110
 - defined, 110
 - disease burden, 110–111
 - fluid therapy trial comparisons, **114**
 - patient risk stratification, 111, **111**
 - preventive interventions
 - bicarbonate, 112, 115
 - contrast agent, 112
 - fluid administration, 112
 - N*-acetylcysteine, **114, 115, 116–117**
 - other agents, 115
 - prophylactic RRT, 115, 118
 - theophylline, 115
 - risk reduction recommendations, **118**
 - trial comparisons, **113**

Index

- COOPERATE study, 174, 219
 Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), 84
 Core Indicators Project (ESRD), 19
 CORR. *See* Canadian Organ Replacement Register (CORR)
 corticoid-sparing agents in frequently relapsing/steroid-dependent SSNS
 alkylating agents, 779
 cyclosporine, 780
 levamisole, 780–781
 mycophenolate mofetil (MMF), 781
 tacrolimus, 781
 corticosteroids. *See also* steroids
 for acute interstitial nephritis, 125–126
 benefits of discontinuation, 593
 deminalization issues, 375
 for FSGS, 152–153
 for HBV-associated nephropathy, 265
 for HSP, **811**
 for idiopathic membranous nephropathy with CsA, **165**
 with cytotoxic agents, 161, 162
 high-risk patients, 162
 medium-risk patients, 160–162
 for IgAN, 175–177
 as immunosuppression maintenance standard, 592–593
 maintenance immunosuppression without, 593–594
 for MCD, 150–151
 for membranous nephropathy, 265
 with MMF and CsA, 593
 for MPGN, **814**
 with type II cryoglobulinemia, 275
 for pediatric nephrotic syndrome, 774–776, 778
 with cyclosporine, 778
 oral corticosteroids, 788, 792
 short course/high-dose IV, 792
 for proteinuria reduction, 177, 787
 for reduced ESRD risk, 177
 SSNS relapse prevention in children, 766, 774, 776
 usage determination, 125–126
 COX-1 cyclooxygenases, 286
 COX-2 cyclooxygenases, 286. *See also* nonsteroidal anti-inflammatory drugs (NSAIDs)
 clinical syndromes associated with
 acute tubulo-interstitial nephritis, 288–289
 ARF/ATN, 288
 chronic kidney failure, 289
 glomerulonephritis, 289
 hyperkalemia/hypoaldosteronism, 289–290
 hypertension, 289
 renal papillary necrosis, 289
 salty/water retention, 289
 effects on renal prostaglandins, 287
 inhibition of renin secretion, 288
 proteinuria reduction for nephrotic syndrome, 290
 renal dysfunction in trials of, 288
 COX-2 mRNA/inducible COX-2 mRNA, 286
 C-reactive protein (CRP), 218
 crescentic Immunoglobulin A nephropathy (IgAN), 175
 crush injuries, as causative for hyperkalemia, 634
 cryoglobulinemia, 272
 crystalline nephropathies, 127–128
 clinical features, 128
 course/management, 128
 defined/etiology/pathogenesis, 127–128, **129–130**
 laboratory findings, 128
 crystalloid vs. colloid fluids, for ARF, 83
 CsA. *See* cyclosporine A (CsA)
 cuffed central venous catheter (CVC), 460
 cuffed CVC-related bacteremia (CRB), 460
 prevention of, 464–465
 RCTs of in hemodialysis patients, **464**
 cuprophane, 143
 cyclophosphamide
 evaluation for MPGN, 187, 189
 for FSGS, 153
 for IgAN (with/without azathioprine), 177–179
 for lupus nephritis
 with azathioprine, 247, 248
 IV administration, 247
 for MCD, 151
 in MPGN with type II cryoglobulinemia, 275
 cyclosporine A (CsA)
 for CAN, 603
 for idiopathic membranous nephropathy, 162, **165**
 for maintenance immunosuppression, 592–596, 706
 with MMF and corticosteroids, 593
 vs. azathioprine with corticosteroids, 592
 vs. tacrolimus, 593
 withdrawal strategies, 594–595
 for MCD, 151
 for pediatric steroid-resistant nephrotic syndrome, 787–788
 for relapsing/steroid-dependent SSNS, 780
 side effects of, 151
 use of during pregnancy, 155
 cystatin C, 74
 as biomarker of renal tubule injury, 75–76
 as endogenous filtration marker, 59
 vs. serum creatinine, for GFR assessment, 74
 cysteamine for cystinosis, 820
 cystinosis
 evidence ratings/recommendations, **819**
 optimal management recommendations, 820
 treatment, 818–820
 cystinuria, 648–649
 cytomegalovirus (CMV)
 acyclovir for, 707
 ganciclovir for, 707
 and transplantation, 539, 563, 566, **566**
 valaciclovir for, 707
 cytomegalovirus (CMV), and transplantation, 539, 563, 566, **566**
 in pediatric patients, 707
 daclizumab monoclonal antibody, 577, 706
 darbepoetin (ESA), 327, 328, **328**, **697**
 DASH studies. *See* Dietary Approaches to Stop Hypertension (DASH) studies
 DATT. *See* dialysis adequacy and transport test (DATT)
 Daugirdas equation, 427, 740
 dCCBs. *See* dihydropyridine calcium channel blockers (dCCBs)
 delayed graft function (DGF), kidney transplantation
 available evidence, 577, 581–582
 definitions, 574
 guidelines, 575–576
 prevention strategies, **581**
 Depner-Daugirdas equation, 427
 Die Deutsches Diabetes Dialyse (4D) study, 437
 diabetes mellitus, 231–240. *See also* Appropriate Blood Pressure Control in Diabetes (ABCD) study; Bergamo Nephrologic Diabetes Complication Trial (BENEDICT) study; Die Deutsches Diabetes Dialyse (4D) study; United Kingdom Prospective Diabetes Study (UKPDS)
 ACEi (captopril) for, 346
 albuminuria for prediction of, **31**
 anemia and, 324
 as cause of ESRD, 12
 CHF and, 407
 as CKD risk factor, **47**, **48**, **209**
 comorbid to peritonitis development, 509
 creatinine clearance measurement for, 111
 DGF and, 575–576
 donor issues, 554
 ESRD association, 48
 HD/PD and, **406**, **473**
 from HIV-1 drug-induced nephrotoxicity, 236
 hypertension and, 200, 208, 209–210, 214–220, 551
 kidney disease prevention and, 239–240
 K⁺ supplementation and, 639
 management of in dyslipidemia, 335, 336
 in MCD, 150–151
 in membranous nephropathy, 160
 from NRTIs, 259
 obesity association with, 554
 organ protection in, 235–236
 during pregnancy, 301–302
 and race/ethnicity, 49
 renovascular disease and, 225, **226**
 risk factor for secondary nocturnal enuresis, 753
 sevelamer and, 372
 as side effect
 of antiretroviral agents, 258, 259
 of beta blockers, 317
 of steroids, 190
 stone formation and, 642–644, 648
 transplantation issues, 335, 339, 535–536, 546, 562, 706
 Vitamin D replacement therapy for, 359
 diabetes mellitus, type 2. *See also* Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study
 ACEi for, 346
 donor issues, 554
 hypertension and, 203
 and idiopathic membranous nephropathy, 233
 intensified blood pressure control, 238–239
 MARVAL study, 238
 progression to ESRD, 231, 232, 233
 renoprotectiveness of ARBs, 316
 diabetic ketoacidosis in children, 614–615
 diabetic nephropathy, 32
 ABCD trial, 216
 albuminuria association, 232
 algorithm for possible diagnosis, **232**

- calcium channel blockade for
 dCCBs, 238
 ndCCBs, 238
 cost-effectiveness analysis, 52
 definitions/diagnosis, 232–233
 outcome, 233–234
 predisposing conditions, 234
 during pregnancy, 301
 proteinuria as cause of, 209
 RAAS blockade renoprotective effect, 211
 ACE inhibitors, 236
 ACEi vs. ARBs, 237
 antialdosterone therapy, 237–238
 ARBs, 236–237
 race/ethnicity prevalence, 220
 stages of, 232
 time-dependent course of, 233
- dialysate buffer
 for CRRT, 143–144
 for dialysis-related hypotension prevention, 453
 for pediatric peritoneal dialysis, 732–734
 dialysis adequacy and transport test (DAT_T), 489
- dialysis membranes, 142, 410–411
 biocompatibility of, 411, 413–415
 characteristics of, 411
 guidelines on characteristics/RRT modality usage, 411
 importance of biophysical properties, 410
 initial problems with, 410
 membrane flux, 412, 415
 RCT reviews, 413, 414, 415
 Renal Association (UK) recommendations, 412, 419
 Dialysis Morbidity and Mortality Study (DMMS), 393, 396, 435
 Dialysis Morbidity Study Wave II, 404
 Dialysis Outcomes and Practice Patterns Study (DOPPS), 21–23, 268
- dialysis-related hypotension, 433
- dialysis therapy. *See also* hemodialysis (HD);
 hemodialysis (HD), infections related to;
 peritoneal dialysis; peritoneal dialysis, salt and
 water balance; peritoneal dialysis, small solute
 clearance; peritoneal dialysis solutions
 adequacy of in pediatric PD, 731–734
 for ARF, 72
 Can-It (Canadian-Italian) Impact Study, 393
 catheter use
 double-cuffed, 397
 tunneled cuffed cannulas, 396
 in children
 childhood phase, 656
 infantile phase, 655–656
 pubertal phase, 656
 CHOICE study, 391, 395, 396
 comorbidities, importance of, 337
 consequences of late referrals for, 334–335
 contraindications, 395
 delivery, 424
 dialysis membranes/studies, 142, 410–411
 dosing target, 425–426
 dyslipidemia and, 334, 335, 336
 for HRS, 93–94
 IDEAL study, 404
 importance of comorbidities, 395
 Kaplan-Meier survival curves, 394
- NECOSAD cohort study, 403–404
 patient counseling about, 393–394, 395
 during pregnancy, 304–305
 preparation for, 391–397
 EPIREL multicenter study, 391, 393
 modality selection, 393–395, 395
 for stage V/lipid-lowering therapy, 91
 starting, determination of
 early start/timely referral, 403
 guidelines/studies, 403–404
 successes of, 13
- dialysis therapy, delivery/adequacy, 423–429
 adequacy
 definition, 425
 recommendations, 428
 approximate equations, use of, 427
 Daugirdas equation, 427
 Depner-Daugirdas equation, 427
 Tattersall equation, 427
 blood urea nitrogen (BUN)
 rebound of, 424, 425
 dosing target, 425–426
 urea reduction ratio (URR), 427
 eKt/V, 424, 425
 residual renal clearance impact on, 426
 Frequent Hemodialysis Network trial,
 429–430
 HEMO study, 424, 428
 NCD5 study, 424, 427–428
 nPCR calculations, 426
 renal urea clearance (Kru), 426
 spKt/V, 424, 425
 stdKt/V, 426–427, 427
 urea kinetic modeling (UKM), 423
 basis/derivation of, 424
- dialysis therapy-related infections
 bacterial, 453
 from dialyzer reuse, 455–456
 guidelines/recommendations
 dialyzer reuse, 457–458, 457
 immunizations, 456
 isolation, 456–457
 water control, 457
 risk factors, 453
 viral, 453–454
 water quality issues, 454–455, 454
- dialyzer reuse, 455–458
 AAMI water purity guidelines, 455, 456
 advantages of, 455
 cleaning/sterilization methods, 455
 disadvantages of, 455
 membrane integrity/clearance changes, 455–456
 mortality and, 456
 Task Force on Reuse of Dialyzers (NKF), 456
- diclofenac (COX-2), 288
- diet and nutrition. *See also* Dietary Approaches to Stop
 Hypertension (DASH) studies; Modification of
 Diet in Renal Disease (MDRD)
 in hemodialysis (HD), 435
 in hyperphosphatemia, 363
 in pediatric hemodialysis, 742
 in pediatric hypertension, 670
 in peritoneal dialysis, 492–493
 in renal stone disease, 643, 644–645, 644
- Dietary Approaches to Stop Hypertension (DASH)
 studies, 216, 645
- dietary protein intake assessment, in hemodialysis
 patients, 435
- dihydropyridine calcium channel blockers (dCCBs)
 for type 2 diabetes, 238
 vs. ARBs, 238
- dihydropyridine calcium channel blockers (DHCCBs),
 209, 316. *See also* amlodipine; felodipine
- diltiazem (ndCCB), 219, 238, 315
- dipyridamole, 190–191
 evaluation for AVG, 463
 evaluation for MPGN, 187, 188, 189
- DIRECT study, 603
- disseminated intravascular coagulation (DIC) during
 pregnancy, 303
- diuretics. *See also* antidiuretic hormone (ADH) levels
 ACEi, 218, 313
 for cardiorenal syndrome, 84
 loop diuretics, 219, 275, 493, 637, 770
 ndCCBs vs., 238
 potassium (K⁺) sparing, 639
 potassium-sparing, 290
 for slowing disease progression, 316
 thiazide diuretics, 219, 619
 hyponatremia association, 621
 with NSAIDs, 289
 stone reduction, 645–646
 vs. ACEi, 218
 vs. ndCCBs for diabetic nephropathy, 238
- diverticulitis, suspicion of, in PD-related infection, 511
- donor (living) evaluation and selection, 545–555
 anatomic evaluation, 553
 components, 546
 consent of donor, 555
 contraindications
 atherosclerotic renal vascular disease, 555
 cardiopulmonary, 545
 diabetes, 554
 pulmonary, 546
 ethnic/cultural considerations, 548–549
 immediate surgical risks
 cardiopulmonary disease, 545–546
 coagulation abnormalities, 546
 ESRD, 550
 hematuria, 551
 microalbuminuria (African Americans), 551
 postoperative venous thrombosis, 546
 self-destructive behavior, 547
- mortality
 long-term, 546–547, 547
 operative/postoperative, 546, 547
- other issues
 age, 554
 infection/malignancy, 555
 obesity, 554
 renal vascular disease, 554–555
- overall process, 545
- post-donation kidney function, 549
- psychological evaluation, 553
- renal evaluation, 548–549
 albuminuria, 551
 donor kidney biopsy, 551
 ESRD, 548–549, 549

Index

- donor (living) evaluation and selection (*Cont.*)
 GFR, 547–548, **548**
 hematuria, 552–553
 hypertension, 551–552, **552**
 nephrolithiasis, 553
 polycystic kidney disease, 553
 proteinuria screening, 550–551, **550**
 TBMD, 552–553
- dopamine
 low-dose, effect on need for RRT, *102*
 for prevention of ATN, 101–102, *102*, 105
- Doppler ultrasound (DU) stenosis (RCTs), 461–462
- DOPPS. *See* Dialysis Outcomes and Practice Patterns Study (DOPPS)
- double-cuffed catheters, 397, **514**
- doxercalciferol (vitamin D₂), 355, 358
- dual-energy X-ray absorptiometry (DEXA)
 measurements, in hemodialysis patients, 435
- dynamic venous pressure (DVP), 460, 462–463, 743
- dyslipidemia in CKD, 220. *See also* lipid lowering therapies; statin therapy
- abnormalities after transplantation, 334–335
- ALERT study, 336
- assessment/diagnosis, 337
- CAPD and, 334
- in hemodialysis patients, 334, 335, 337, 338, 339, 436–438
- impact on CVD
 dialysis, 335, 436
 nephrotic syndrome, 335
 transplantation, 335–336
- intervention for transplantation, 568–569
- lipid lowering therapies
 CKD stages 1–4, 335
 transplant recipients, 336
 CKD stage V: dialysis, 336
 for high LDL, 338–339
 for low HDL, 339
 principles of, 337
 renal end point studies, 337
 for very high triglycerides, 338
 with non-HDL cholesterol, 339
- from NRTIs, 259
- in pediatric patients, 673–678
 evidence ratings/recommendations, **675**
 lifestyle modifications, 674
 statin therapy, 674–675
- proteinuria and, 333–334, 337
- type 2 diabetes and, 234
- eclampsia, therapy during pregnancy, 105, **298**, 395, 397–402
- Ecstasy (drug) and hyponatremia, 621
- eculizumab, 166, 191, 193
- edema in children, 770
- elderly people. *See also* Evaluation of Losartan in the Elderly (ELITE) study
 ACEi/ARB monitoring, 160
 acute renal failure (ARF) in, 31
 celecoxib and, 287
 DGF and, 575
 growth of ESRD population, 474
 hypertension in, 201, 207–209
 minimal change disease in, 150–151
- NSAIDs and, 288, 289
- peritoneal dialysis and, 474
- risk factors
 for CKD, 46
 for MCD, 150–151
 osteoporosis, 375
 sevelamer studies, 372
 thiazide diuretics and, 646
 transplantation in, 10, 535
 Vitamin D studies, 357
- electrolyte and acid-base disorders. *See* acid-base disorders
- EMC. *See* essential mixed cryoglobulinemia (EMC)
- enalapril, 84, 252, 268, 295, 297, 314, 316, 749
- endocarditis, infected, related to hemodialysis (HD), 442
- end-stage renal disease (ESRD)
 blood pressure and, 347
 cancer's commonness in, 538
 children with, 669
 definition, 3
 diabetes, type 2, progression to, 231, 232, 233
 diabetes as cause of, 12
 diabetes mellitus association, 48
 HAART for, 253
 hepatitis B virus and, 268–269
 HIVAN/collapsing glomerulopathy progression to, 253
 from idiopathic membranous nephropathy, 158
 IgAN progression to, 171, 172, 177
 living donor evaluation, 548–549, **549**
 MCD/FSGS progression to, 150
 and mortality, risk associated with CKD, 61–64
 MPGN progression to, 186
 during pregnancy, therapy for, 304–305
 race, influence of on, 9, 11, 49
 rates of, Black people vs. White people, 9
 sepsis rates, 452
- End-Stage Renal Disease Clinical Performance Measures (ESRD-CPM) Project Database, 19–20
- entecavir, 266
- Enterobacter* bacteremia, 453
- Enterococcus* spp., 512
- environmental nephrotoxins (heavy metals)
 cadmium, 296–297
 lead, 294–296
 mercury, 296
 silicon, 297
 solvent nephropathy, 297
- EPIREL multicenter study, 391, 393
- Epstein-Barr virus, 539, 707
- equilibrated Kt/V (eKt/V)
 calculations using end-dialysis BUN, 424, 425
 residual renal clearance impact on, 426
- ERA-EDTA. *See* European Renal Association-European Dialysis and Transplant Association Registry (ERA-EDTA)
- ergocalciferol, 359
- erythropoiesis-stimulating agents (ESAs) therapy, 327–328, 696, **697**, **698**
- ESRD. *See* end-stage renal disease
- essential mixed cryoglobulinemia (EMC), and hepatitis B virus, **264**, 267–268
- ethylene glycol poisoning, 132
- Euro-Lupus Nephritis Trial, 247
- European Association of Urology, 643
- European Best Practice Guidelines (EBPG), 215
 for dialysis membranes, 412
 induction therapy, 575
 for peritoneal dialysis, 403
- European Dialysis and Transplantation Association, 305
- European Pediatric Peritoneal Dialysis Working Group, 694, 696
- European Renal Association-European Dialysis and Transplant Association Registry (ERA-EDTA), 21
- European Society of Cardiology, 200
- European Society of Hypertension, 200
- Evaluation of Losartan in the Elderly (ELITE) study, 83
- EVEREST trial, 629
- everolimus (EVL), 603
- exit site and tunnel infections, 510. *See also* peritoneal dialysis-related infections
 evidence rating/recommendations, for pediatric PD patients, **728–729**
 treatment of, 511, 523–524
 antimicrobial agents, 512, **513**, 516, **517**, 520–521
 catheter-related interventions, **521**
 double bag vs. Y-systems, 523
 intraperitoneal vancomycin, 523–524
 Y-set vs. standard spike catheters, 522
- extracorporeal albumin dialysis (MARS) system, 94
- ezetimibe (for lipid-lowering), 339–340
- Fanconi syndrome (lead poisoning), 294, 297, 818
- fast peritoneal equilibration test (PET), 489
- felodipine, 347, 351
- fenopropfen, **123**, 288, 289
- fibrillary glomerulonephritis, 184, 192
- fibromuscular dysplasia, 202, 226–227, 554–555
- fish oil
 for adult IgAN, 179–180, **179**
 for dyslipidemia/triglycerides, 338, 339, 674
 with low-dose aspirin, for AVG, 463
- Fluids and Catheter Treatment Trial (ARDS Network group), 81
- fluid therapy for ARF, 82–83
- fluvastatin, 336–337, 338
- focal segmental glomerulosclerosis (FSGS), 159, 254, 263.
See also HIV-associated nephropathy (HIVAN)
 and collapsing glomerulopathy
 defined/described, 149
 HCV presence in, 272
 from hepatitis B virus, **264**
 management, 152
 natural history, 152
 progression to ESRD, 150
 treatment recommendations, **154**
 alkylating agents, 153
 corticosteroids, 152–153
 MMF, 153
 plasmapheresis, 155
 sirolimus, 153
 tacrolimus, 153
- foscarnet, 127
- Framingham Heart Study, 43, 235, 609, 610
- Framingham Offspring Study, 43
- Frequent Hemodialysis Network (FHN) trial, 429–430
- frequently relapsing nephrotic syndrome, 765, 777, 778
 corticosteroid-sparing agents

- alkylating agents, 779
 cyclosporine, 780
 levamisole, 780–781
 mycophenolate mofetil, 781
 tacrolimus, 781
 corticosteroid treatment, 778
 Fresenius Medical Care North America (FMCNA) system, 424
 FSGS. *See* focal segmental glomerulosclerosis (FSGS)
 fungal infections, in pediatric renal transplantation, 708
- Gambro Healthcare, dialysis center survey, 453
 gentamicin, 444–446, **464**, 465, **483**, 512
 Georgia Division of Public Health, 454
 German Collaborative Glomerulonephritis Study Group, 189
 Gitelman's syndrome, 615
 glomerular filtration rate (GFR)
 annual decline by clinical history, **44**
 assessment, serum creatinine vs. cystatin C levels, 74
 association with cardiovascular disease, 43
 in children with hypertension/CVD in CKD, 671
 decrease of
 with ATM, 97
 with fish oil, 179
 with smoking, 36
 determinations for MN, 159
 effects of BP goal/selection of antihypertensive agents, 210
 estimated reductions/risks, **2**
 estimating equation, 4
 estimation of, 58–61
 HRS association, 88
 limitation of, for treatment/prevention of CKD, **3**
 living kidney donor evaluation, 547–548, **548**
 loss and risk of natural progression, 311
 measurement of, 208
 in MPGN, 185
 in pediatric renal transplantation, 705
 predictive equations, **60**
 during pregnancy, 299, 300–301
 reductions of, from excretion of K⁺, 634
 renal prostaglandins and, 287
 risks associated with
 all-cause mortality/cardiovascular events, 63
 progression to ESRD, 61–63
 serum creatinine association with, 4, 23, 26, 29–30
 for stage 5 CKD, 10
 TIPS improvement of, 93
 Toronto Glomerulonephritis Registry, 159
 type 2 diabetes and, 232
- glomerulonephritis. *See* acute glomerulonephritis; chronic glomerulonephritis
 glomerulosclerosis. *See* focal segmental glomerulosclerosis (FSGS)
 glucocorticoid-induced osteoporosis in pediatric CKD, 685–687
 glucocorticoid remediable aldosteronism, 202
 glucocorticoids
 causative for hypokalemia, 638
 combined with
 CNI and MME, 604
 HAART, 258
 hypertensinogenic contributions of, 669
- long-term toxicity from, 251
 mechanisms of action, 810–812
 gout, 111, 403, 752, 757
 graft rejection, kidney transplantation
 6 months/1 year, anti-CD25 vs. placebo, **580**
 antibody use for, **584–585**
 vs. Muromonab, **588**
 vs. steroids, **586, 587**
 available evidence, 582–583, 586
 definitions, 574–575
 guidelines, 576
 growth hormone (GH)-insulin like growth factor, 654
 growth phases of children. *See under* children
- HAART. *See* highly active antiretroviral therapy (HAART)
 hamartoma, 202
 HBV-associated MPGN. *See* hepatitis B virus (HBV)-associated membranoproliferative glomerulonephritis (MPGN)
 Health Care Financing Administration. *See* Centers for Medicare & Medicaid Services (CMS)
Healthy People 2010, 20
 Heart Outcome Prevention Evaluation (HOPE) study, 235, 239
 heavy metal environmental nephrotoxins, **295**
 cadmium, 296–297
 lead, 294–296
 mercury, 296
 silicon, 297
 solvent nephropathy, 297
Helicobacter pylori screening, in transplantation, 540
 HELLP syndrome, 303–304
 hemangiopericytoma, 202
 hematuria
 living donor evaluation, 552–553
 microscopic, in HCV-associated MPGN, 273
 hemodiafiltration (HDF), 363, 410–419, 431. *See also* continuous venovenous hemofiltration (CVVH)
 hemodialysis (HD), 3. *See also* dialysis therapy; pediatric hemodialysis; vascular access for hemodialysis
 CHOICE study, 391
 contraindications, **395**
 dyslipidemia
 and CVD, 436
 management of, 436–438
 pattern/prevalence, 435
 dyslipidemia and, 334, 335, 337, 338, 339
 first successful accomplishment of, 410
 home hemodialysis, 395
 for hyperkalemia, 636
 hypertension control, 433
 for hypokalemia, 431–432
 hypotension, dialysis-related, prevention, 433
 infection susceptibility in, 441–447
 international recommendations, 429
 metabolic acidosis, correction of, 432–433
 mortality vs. peritoneal hemodialysis
 Europe, **406**
 North America, **405**
 negatives-positives of, 404–407
 nutrition assessment/management, 433–435
 dietary protein intake es, 435
- lean body mass, 435
 malnutrition management, **434**, 435
 markers of visceral protein stores, 435
 RCTs, **436**
 subjective global assessment (SGA), 434
 for older patients, 395
 peritoneal dialysis vs., as RRT, 471, **472**
 types of catheter for, 396
 uselessness against radiocontrast toxicity, 227
 vascular access for, 392
 vascular access planning
 vitamin D and, 358
 vs. peritoneal dialysis, for pediatric patients, 723–724
 hemodialysis (HD), access-related infections, 441–447.
See also dialysis-therapy related infections; nosocomial infections in dialysis patients
 diagnostic criteria, **446**
 prevention of
 antibacterial lumen locks, 444–445
 cannula characteristics, 444
 exit site cleaning/skin care, 444
 insertion of catheters, 444
 sources of, 442
 treatment strategies, 445–447
 hemodialysis (HD), infections related to
 hospital acquisition of, 442
 vascular access infections, 442–443
 hemodialysis (HD) therapy, patient management, 431–438
 Hemodialysis (HEMO) study, 428
 hemodialyzer, choice of, in RRT, 142
 hemodynamic management (goal-directed) for ARF, 82–83
 hemofilter, choice of, in RRT, 142
 hemoglobin targets (in CKD), 324–327
 blood pressure, 327
 dialysis adequacy/change in GFR, 327
 hemodialysis access, 327
 left ventricle size, 327
 mortality/cardiovascular events, 324, 327
 quality of life, 327
 transfusions, 327
 hemolysis, 97, 219, 399, 550, **730**
 hemolytic anemia, **124**, 258, 273, 275, 634
 hemolytic uremia syndrome (HUS), 183, 202, 303–304, 540, 709
 HEMO study, 415, 416, 452, 738, 739–740
 Henoch-Schönlein purpura (HSP) nephritis, 202
 epidemiology, 808
 etiology, 807
 evidence rating and therapy recommendations, **811**
 natural history, 808
 therapies/efficacy of therapies, 808–810, **809, 810**
- heparin
 antibacterial properties, 444
 with aspirin, in thrombotic events, 302
 covalently linked, 444
 in dyslipidemia, 338
 evaluation for pediatric use, 178
 in hemodialysis patients, **464**, 673
 in hypertensive/hyperlipidemia management, 275
 intraperitoneal, at PD catheter insertion, 726
 unfractionated, for RRT/AKI anticoagulation, 142–143

Index

- heparin-induced thrombocytopenia (HIT), 143
- hepatitis B and C viruses
 HAART renal complications, 253
 membranous nephropathy association, 158
- hepatitis B virus (HBV)
 dialysis related, 453–454
 epidemiology, 264
 and ESRD, 268–269
 and essential mixed cryoglobulinemia (EMC), **264**, 267–268
 and FSGS, 268
 and IgAN, 268
 isolation practices for, 456
 in kidney transplantation patients, 268–269
 and polyarteritis nodosa (PAN), 267
 renal manifestations, 263
- hepatitis B virus (HBV)-associated
 membranoproliferative glomerulonephritis (MPGN)
 clinical manifestations, 265
 transplantation issues, 539–540
 treatment
 adefovir dipivoxil, 266
 alpha interferon (IFN- α), 265–266
 corticosteroids, 265
 entecavir, 266
 infliximab, 266
 lamivudine, 266
 vaccination, 266–267
- hepatitis B virus (HBV)-associated membranous nephropathy (MN)
 clinical course, 264–265
 pathophysiology, 264
- hepatitis C virus (HCV)
 dialysis related, 453–454
 genotypes of, 272
 glomerular disease associated with, 272
 isolation practices for, 456–457
 prevalence of, 272
 role in MPGN with type II cryoglobulinemia, 272–276
 clinical manifestations, 273
 pathology, 273–274
 treatment, 274–276, **275**
 triggering mechanisms, 272
 transplantation issues, 539
- hepatitis GB virus C, 454
- hepatitis G virus, 454
- hepatorenal syndrome (HRS)
 clinical diagnosis, **90**, **90**
 clinical features, 89–90
 defined/types of, 88
 management, 90–94, **91**
 nonpharmacological therapy, 93–94
 pharmacological therapy, 91–93
 pathogenesis, 88–89, **89**
 arterial vasodilation, 88
 reduced cardiac output, 88–89
- heroin nephropathy, 253
- high-density lipoprotein (HDL) levels, in hemodialysis patients, 435, 436
- high-flux dialysis membranes, 411
- highly active antiretroviral therapy (HAART)
 for end-stage renal disease, 253
 for HIVAN/collapsing glomerulopathy, 257, **257**
 with ACEi/ARBs, 260
 renal damage caused by, 258
- Hispanics
 diabetes mellitus in, 49
 FSGS in, 763, 764
 HIV-associated glomerulonephritis in, 258
 living donor statistics, 548
 systemic lupus erythematosus in, 244
- HIT. *See* heparin-induced thrombocytopenia (HIT)
- HIV-1 drug-induced nephrotoxicity
 antiretroviral therapy, indirect effects, 259
 crystallization mechanism, 258
 drug interactions, 258–259
 tubular cytotoxicity, 259
- HIV/AIDS and hyponatremia, 620–621
- HIV-associated glomerulitis, 258
- HIV-associated nephropathy (HIVAN) and collapsing glomerulopathy
 background/clinical manifestations, 253–254
 incidence of death statistics, 254
 management of, 260
 pathogenesis of, **256**
 HIV-1 infection of renal epithelium, 254–256
 host factors, 256
 viral genes, 256
 pathology of, 254
 progression to ESRD, 253
 treatment of
 ACE inhibitors, 257–258
 HAART, 257
 immunosuppressive therapy, 258
- HIV Medicine Association of the Infectious Diseases Society of America, 260
- Hixton Retreat of the Dense Deposit Disease Focus Group, 191
- home hemodialysis, 395
- HOPE study, 43, 45, 46
- hospital acquired ATN, 99
- hospital acquired infections
 acute kidney dysfunction, 71
 acute tubular necrosis, 99
 from hemodialysis, 442
- HRS. *See* hepatorenal syndrome (HRS)
- human polyomavirus type 2 (JC) virus, 277
- hydrochlorothiazide, 235, 552, 670
- hydronephrosis, 85, 282
- Hygiene Hypothesis of MPGN type 1 (Johnson), 184
- hyperaldosteronism, 204, **204**, 615, **615**, 637, **638**
- hypercalcemia
 AKI and, 126, 127
 from calcitriol, 358, 685
 calcium carbonate/calcium salts and, 365, 367, 372, 644
 oversuppression of PTH by, 368
 primary hyperparathyroidism and, 643
 sevelamer and, 685
 vitamin D therapy and, 359
- hyperfiltration, as CAN mediator, 601
- hyperglycemia
 as cause of nonhypotonic hyponatremia, 619
 diuretic induction of, 313
 and IV methylprednisolone/dexamethasone therapy, 792
 metabolic syndrome and, 234
 need for control in diabetes, 493
 as risk factor of hypertension, 215
 risk of from ACEi/ARBs/aldosterone antagonists, 238
 treatment for with high glycerides, 338
- hyperkalemia
 causes/contributory factors, 431, 634–635, **634**
 clinical features, 633
 from COX-2 cyclooxygenases, 289–290
 treatment of, 431–432, **635**
 β_2 -agonists, 636
 bicarbonate, 636
 calcium (Ca²⁺) gluconate chloride, 635
 hemodialysis, 636
 insulin, 635–636
 sodium polystyrene sulfonate, 636
- hyperkalemic distal RTA (type IV RTA), 614
- hyperosmolality, association with hyperkalemia, 634
- hyperoxaluria, and transplantation, 540
- hyperparathyroidism, 297, 318, 671–672. *See also*
 primary hyperparathyroidism; secondary hyperparathyroidism
 correlation with LVH in adults, 671–672
 disordered bone deficiency in, 358
 in nosocomial infections, 453
 PTH levels and, 682
 underlying to uremic dyslipidemia, 673
 vitamin D deficiency in, 356
- hyperphosphatemia, 358, 360, 363–373
 CARE II trial, 369
 RIND trial cohort, 371
 treatment strategies, 363–373
 calcium-based phosphate binders, 367–369
 metal salt phosphate binders
 aluminum salts, 365
 lanthanum-carbonate, 365–366
 non-metal-based phosphate binders
 calcium carbonate/calcium acetate, 367
 magnesium salts, 366–367
 phosphate-restricted diet, 363
 sevelamer
 effects on bone histology, 371–372
 use determination, 372
 vs. other phosphate binders, 369–371, **370**, 372–373
- hyperreninemia, 637, **638**
- hypertension (HTN). *See also* angiotensin converting enzyme inhibitors (ACEi); angiotensin receptor blockers (ARBs); blood pressure; calcium channel blockers; dihydropyridine calcium channel blockers (DHCCBs); dyslipidemia in CKD; Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study; nondihydropyridine calcium channel blockers (NDHCCBs); individual drugs
 in African Americans, with CKD, 220
 as CAN mediator, 601
 as cause/consequence of kidney disease, 202–203
 from CKD, 3, 46, **47**
 classifications, 200, **201**, 202–203
 clinical conditions/etiology, **202**
 from COX-2 cyclooxygenases, 289
 creatinine clearance measurement for, 111
 definitions/general considerations, 200, **201**
 diabetes mellitus and, 208, 209–210, 214–220

- GFR declines, 44
 goal in CKD, 347
 from HBV with PAN, 267
 in HCV-associated MPGN, 273, 274–275
 hemodialysis and, 433
 lead-induced, treatment of, 295
 living donor evaluation, 551–552, **552**
 lowering, as CKD treatment strategy, 31–33
 lower readings in Tac-treated patients, 593
 as lupus nephritis risk factor, 246
 metabolic syndrome and, 234
 in minimal change disease, 149
 misclassification in clinics, 345
 from NRTIs, 259
 patient evaluation, 203–204, **204**
 during pregnancy, 303, 305–306
 residual renal function (RRF) and, 480
 and risk of CKD, 214
 treatment decisions, 215, 347–351
 DASH studies, 216
 type 2 diabetes and, 233
 hypertension (HTN) in children, 669–673
 blood pressure measurements, 669–670
 carotid artery intima media thickness (IMT), 672
 CKD as causative, 669
 C-reactive protein levels, 672
 Fourth Report recommendations, 671
 left ventricular mass (LVM), 670–672
 National High BP Education Program, 669, 670
 prevention/treatment strategies, 670, 672–673
 evidence ratings/recommendations, **671, 674**
 hypertension in chronic kidney disease (CKD)
 mechanisms of, 215
 risk of CKD progression, 214–215
 risk stratification of CKD-CVD, 218–220
 treatment decisions
 management algorithm, 217
 medication choices, 218
 nonpharmacological interventions, 216
 onset of treatment, 215
 pharmacological interventions, 216
 targeting BP levels, 216–217
 targeting proteinuria, 217–218
 Hypertension Optimal Treatment Study, 43
 hypertensive renal damage
 diagnosis of
 GFR measurement, 208
 urinary albumin/protein excretion quantification, 208
 evidence for, 207–208
 prevention/treatment
 blood pressure targeting, 209–210
 RAAS blockade (specific benefit), 210–211
 hyperuricosuria, 644–648
 hypoaldosteronism, 288, 289–290, 614, 634
 hypocalcemia, 358
 hypocitraturia, 646
 hypocomplementemia, 190
 hypokalemia, 432
 causes, 637, **638**
 clinical features, 637
 thiazide association, 645
 treatment, 637–639, **639**
 intravenous K⁺ replacement, 638
 K⁺-sparing diuretics, 639
 magnesium (MG2+) repletion, 638–639
 oral K⁺ replacement, 638
 hypomagnesemia, 99, 733, **734**
 hyponatremia, 618–630
 clinical manifestations, 618–619
 postoperative hyponatremia, 730
 psychogenic polydipsia, 629–630
 EVEREST trial, 629
 incidence, morbidity, mortality
 cerebral salt wasting, 620
 cirrhosis, 621
 congestive heart failure, 621
 drugs, 621
 general hospital setting, 619
 HIV/AIDS, 620–621
 marathon runners, 620, 630
 nursing home patients, 619
 postoperative, 620
 psychogenic polydipsia, 619–620
 treatment recommendations
 acute hyponatremia, **625**, 629–630
 chronic asymptomatic hyponatremia, **627**, 628–629
 chronic hyponatremia, **626**, 630
 hyponatremic encephalopathy, 621–622, 628
 hyponatremic encephalopathy, 621–622, 628
 hypoproteinemia, 288
 hypotension
 acute tubular necrosis and, 97–98, 101
 ATN risk from, 101
 defense against during pregnancy, 300
 dialysis-related, 93, 413, 433
 fenoldopam-induction of, 103
 HF vs. HDF, 418
 high-flux HD vs. low-flux HD, 412
 in metabolic acidosis, 432
 orthostatic, in elderly patients, 201
 pre-renal failure and, 80, 84
 propensity for during IHD, 140
 in women with Itai-Itai disease, 297
 hypotonic hyponatremia, 618
 hypouricemic therapy, 131

 ibuprofen, **123**, 289
 icodextrin, 482, 493, **494**, 503–504
 IDEAL study (of dialysis start time), 404
 IDEC-131, for lupus nephritis, **249**, 250
 idiopathic membranous nephropathy (MN)
 from hepatitis B virus, **264**
 type 2 diabetes and, 233
 idiopathic nephrotic syndrome (INS). *See* focal segmental glomerulosclerosis (FSGS); minimal change disease (MCD)
 idiopathic steroid-resistant nephrotic syndrome in children. *See* steroid-resistant nephrotic syndrome
 IFN-induced nephrotoxicity, 266
 IgAN. *See* Immunoglobulin A nephropathy (IgAN)
 immunoglobulin A nephropathy (IgAN), 263
 in adults
 evidence, 173–174
 immunosuppressive treatments, 177–180
 natural history, 170–171
 recommendations, 173
 in children
 evidence, 174
 immunosuppressive treatments, 177–180
 natural history, 171
 recommendations, 173
 risks of, 709
 comorbidities
 isolated microscopic hematuria and proteinuria, 175
 with nephrotic syndrome, 176
 with rapidly declining GFR, 175–176
 with recurrent microscopic hematuria, 174–175
 with slowly progressing renal impairment, 176–177
 COOPERATE study, 174
 HCV presence in, 272
 from hepatitis B virus, **264**
 and HIV-associated glomerulonephritis, 258
 methods, 172–173
 during pregnancy, 303
 prognostic factors, 171–172, **173**
 treatment recommendations
 ACEi/ARBs, 173–174
 RAS blockade, 173
 immunological injury, from CAN
 acute rejection episodes, 600
 antibody-mediated rejection, 600–601
 subclinical rejection, 600
 immunosuppressive therapy
 after transplantation, for CVD, 569
 as cause of hepatitis B virus, 268–269
 for chronic allograft nephropathy, 604
 definitional concerns, 592
 from DGF, 577
 for infection-related nephropathies, 258
 for lupus nephritis, 247
 for membranous nephropathy, 159–162
 meta-analysis for nephrotic syndrome in adults, 188
 in MPGN with type II cryoglobulinemia, 275
 pediatric concerns, 767
 for proliferative lupus nephritis, 247
 for PVAN, 280
 with steroids, for MPGN, 191
 indomethacin, 287, 289, **716, 819**, 820
 induction therapy, for kidney transplantation, 705–706
 available evidence, 576–577
 definitions, 574
 guidelines, 575
 interleukin-2 receptor antagonists, 705–706
 OKT3 vs. cyclosporine A, 706
 infection-related nephropathies, 253–260
 HIV-1, drug-induced nephrotoxicity of
 antiretroviral therapy, indirect effects, 259
 drug interactions, 258–259
 mechanisms, 258
 tubular cytotoxicity, 259
 HIVAN/collapsing glomerulopathy
 background/clinical manifestations, 253–254
 host factors, 256
 pathogenesis, 254–256
 pathology, 254
 treatment, 256–258
 HIV-associated glomerulonephritis, 258
 thrombotic microangiopathy, 258

Index

- infections related to hemodialysis (HD). *See also*
nosocomial infections in dialysis patients
access-related infections
prevention of, 444–445
treatment strategies, 445–447
diagnostic criteria, **446**
sources of, 442, **443**
vascular access infections, 442–443
- infections related to peritoneal dialysis (PD)
BRA/CARI guidelines, 511, 512
catheter-related interventions, **518**
effects of interventions, **519**
exit site/tunnel infections (*see* exit site and tunnel infections)
in pediatric patients, 727–731
peritonitis (*see* peritonitis)
randomized controlled trials
of antimicrobial agents, **513**
of catheter-related interventions, **514**
characteristics of interventions/populations, **515–516**
- Infectious Diseases Society of American, 277
- infliximab, 266
- insulin and hyperkalemia, 635–636
- insulin resistance
from antiretroviral agents, 258, 259
in metabolic acidosis, 432
in microalbuminuria in type 1 diabetics, 234
from NRTIs, 259
tacrolimus causative for, 788
as therapeutic target in PD patients, 334
type 2 diabetes and, 233
uremic dyslipidemia in, 673
- interleukin-18 (IL-18), 75, 77
- intermittent hemodialysis (IHD), 137
CRRT vs., 139–140
CVVH vs., 140
treatment frequency study, 141
- International Ascites Club, 88
- International Classification of Diseases*, 9th Revision,
Clinical Modification (ICD-9-CM), 74
- International Pediatric Peritoneal Registry, 730
- International Society for Peritoneal Dialysis (ISPD), 490, 511, 730
- International Society of Hypertension, 200
- International Society of Nephrology and the Renal Pathology Society (ISN/RPS), 245
- International Study of Kidney Disease in Children (ISKDC), 188, 763–764, 787
- International Verapamil-Trandolapril Study (INVEST), 32–33, **33**
- interstitial fibrosis, 159, 599
- interstitial nephritis. *See also* acute interstitial nephritis (AIN); acute tubulo-interstitial nephritis
histological correlates of AKF with IFN therapy, 266
indinavir crystals causative for, 258, **259**
during pregnancy, 303
in pregnant women, 303
reduction from deletion of *nef* from transgenic line, 256
- intervertebral discitis, related to hemodialysis (HD), 442
- intradialytic parenteral nutrition, 659–660
- irbesartan, 32, 35, 374, 378
- Irbesartan in Diabetic Nephropathy Trial (IDNT) study, 32, 34, 374
- Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study, 35
- IRMA 2. *See* Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study
- iron therapy (for anemia in CKD)
formulation comparison, **329**
modes of administration, 329–330
status markers, 328–329
- ischemia-related ATN, 101
- ischemic heart disease, 479, 535, 567, 568
- ischuria renalis*. *See* acute renal failure (ARF)
- isolated ambulatory hypertension, 200, **201**
- isolated diastolic hypertension, 200, **201**
- isolated systolic hypertension, 200, **201**
- isolation for dialysis-infected patients, 456–457
- Israel Penn International Tumor Transplant Registry, 538
- Itai-Itai (ouch-ouch) disease, 297
- Japan
CVD studies, 725–726
dialysis survival studies, 433
ESRD data, 13, 171, 203
HBV infection comparisons, 268
Itai-Itai disease, 297
microscopic hematuria data, 552
mizoribine studies, 792
proteinuria/CKD data, 214
RCT of corticosteroids, 177
transplantation rates, 574
transplantation statistics, 574
22-oxalocalcitriol development, 685
- Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-7), 215
- Journal of Clinical Investigation*, 71
- Kaiser Permanente CKD study, 214
- Kaplan-Meier survival curves, for patients starting dialysis therapy, 394
- Kayexalate (sodium polystyrene sulfonate), 636
- K/DOQI. *See* Kidney Disease Outcomes Quality Initiative (K/DOQI)
- “Kidney Disease: Improving Global Outcomes (KDIGO)” Controversies conference, 4–5
- Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines, 19, 22, 26–27, 33
albuminuria measurement guidelines, 61
AVF targets/recommendations, 396
bone metabolism issues in children, 685
BP-CKD studies, 214–215, 216
clearance target guidelines, 478–480
clinical anemia in children, 693–694, 699
CVD risks of transplantation patients, 567
dialysis membrane guidelines, 412
dialysis recommendations
control of blood pressure, 433
dosing targets, 425
for iPTH reductions, 359
removal of infected HD lines, 446, **446**
reuse issues, 456
for start of dialysis determination, 404
DVP/SVP measurement standards, 462–463
HDL/LDL limit recommendations for dialysis patients, 435
- mineral and bone disease guidelines, 355, 360
- nutritional management of children, 659
- pediatric hemodialysis, 740
NIVM for UF modeling, 741
nutrition management, 742
vascular access, 742–743
- peritoneal function assessment, 490
- phosphate binder recommendations, 365
- recognition of negative effects of metabolic acidosis, 614
- renal anemia management in children, 672
- RRT guidelines, 391
- sevelamer usage recommendations, 372
- statins for hypercholesterolemia in transplant recipients, 569–570, **570**
- Workgroup on Peritoneal Dialysis, 403
- kidney donors. *See* donor (living) evaluation and selection
- Kidney Early Evaluation Program (KEEP), 18, 23–24
- kidney injury molecule-1 (KIM-1), 75, 76
- Kidney Learning System, 26
- kidneys during pregnancy
anatomical/functional changes, 299
acid-base regulation, 300
blood pressure regulation, 300
hemodynamics, 299–300
volume regulation, 300
water metabolism, 300
- assessment of renal function, 300–301
- diseases
acute fatty liver, 304
acute tubular necrosis, 304
chronic glomerulonephritis, 302
chronic pyelonephritis, 303
development during pregnancy, 303
first diagnosis during pregnancy, 303
polycystic kidney disease, 302
systemic illness association, 301
thrombotic microangiopathy, 303–304
urinary tract obstruction, 304
- ESRD therapy, 304–305
hypertension disorders, 305–306
preeclampsia screening, 306
- kidney stones. *See* renal stone disease
- The Kidney-Structure and Function in Health and Disease* (Smith), 71
- kidney transplantation. *See also* pediatric kidney transplantation
blood pressure and, 208
choice of surrogates/composite outcomes, 563
delayed graft function (DGF)
definitions, 574
guidelines, 575–576
graft rejection
definitions, 574–575
guidelines, 576
hepatitis B virus and, 268–269
immunosuppression
induction trends, **562**
maintenance, 706–707
induction therapy, 705–706
available evidence, 576–577
definitions, 574
guidelines, 575

- infections after
 CMV/recommendations, 563, 566, **566**
 immunosuppression regimens, 569
 UTIs/management strategies, 566–567
- lipid abnormalities after, 334
- maintenance immunosuppression, 592–596
 during pregnancy, 305
 reduced comorbidities of patients, 12
 study of waiting list patients, **564–565**
 survival advantages, **536**, 562
- kidney transplantation, candidate selection/evaluation,
 535–541. *See also* donor (living) evaluation and
 selection
- evidence
 cancer, 538
 cardiovascular disease, 535–537
 cerebral vascular disease, 537
 compliance and adherence, 541
 gastrointestinal disease, 540
 infections, 539
 liver disease, 539–540
 obesity, 541
 peripheral vascular disease, 537
 pulmonary disease, 537–538
 recurrent disease, 540–541
 systemic disease, 540
 urological issues, 541
- recommendations
 cancer, 538
 cardiovascular disease, 535
 cerebrovascular disease, 537
 compliance and adherence, 541
 gastrointestinal disease, 540
 infections, 539
 liver disease, 539
 obesity, 541
 peripheral vascular disease, 537
 pulmonary disease, 537
 recurrent disease, 540
 systemic disease, 540
 urological issues, 541
- kidney transplantation, predictors of outcomes, 561–570.
See also cardiovascular disease and
 posttransplantation outcomes
- cardiovascular disease
 interventions for risk reduction, 568–570
 performance of risk assessment strategies,
 567–568
 rationale for risk assessment, 567
- definitions, 561
 HLA matching, 561–562
 reliability of predictors, 562–563
 survival advantages, **536**, 562
 Kaplan-Meier half-life, 562
 short-term vs. long-term graft, 562
- Kimmelstiel-Wilson glomerulosclerosis, 36
- Kt/V_{urea} , as proxy for small solute clearance, 478, 479,
 480
- lactic acidosis, 613–614
- lamivudine
 for HBV-associated MPGN, 266, 268
 for HBV with active viral replication, 539–540
- lanthanum-carbonate, for hyperphosphatemia, 365–366
- lead (environmental nephrotoxin), 294–296
- lead-induced hypertension, 295
- lean body mass change assessment, in hemodialysis
 patients, 435
- leflunomide, 180, 280, **281**, **602**, 604, 708
- left ventricular mass (LVM) in children with
 hypertension/CVD, 670–672
 anemia association, 672
 cut-off levels controversy, 671
 factors associated with, 671–672
- levamisole for relapsing/steroid-dependent SSNS,
 780–781
- Liddle's syndrome, **615**, 637, **638**
- LIFE study. *See* Losartan Intervention for End Point
 Reduction in Hypertension (LIFE) study
- lipid lowering therapies. *See also* dyslipidemia in CKD;
 statin therapy
- cardiovascular end point studies
 CKD (stages 1–4), 335
 transplant recipients, 336
 CKD stage V: dialysis, 336
 for high LDL, 338–339
 BASs in transplant recipients, 339
 with no statins, 338
 patients unable to take statins, 338
 statins, 338
 TLC, 338
 isolated low cholesterol, 339
 for non-HDL cholesterol with high triglycerides,
 339
 principles of, 337
 renal end point studies, 337
 for very high triglycerides, 338
 with non-HDL cholesterol, 339
- lipoprotein classes of human plasma, **334**
- lisinopril (ACE inhibitor), 238, 351
- liver transplantation, 73, 74, 158–159, 161, 163, 259
- living kidney donors. *See* donor (living) evaluation and
 selection
- loop diuretics, 219, 275, 493, 637
 for prevention of ATN, 101, 105
 resistance to, 84, 770
- losartan, 34, 83, 374, 604
- Losartan Intervention for Endpoint Reduction in
 Hypertension (LIFE) study, 234, 239
- lovastatin, 338, 674
- low-density lipoprotein (HDL) levels, in hemodialysis
 patients, 435, 436. *See also* dyslipidemia in
 CKD; lipid lowering therapies
- lumen locks, antibacterial, 444–445
- lupus nephritis, 184
 definition/epidemiology of, 244
 diagnosis/monitoring of, 244–245
 outcome, 245–246
 during pregnancy, 302
 renal pathology, 245
 treatment of, 246–250
 general, 246
 immunosuppressive therapy, 247–248
 induction therapy resistant patients, 249
 membranous nephropathy, 250
 mycophenolate mofetil, 248
 new treatments, 249–250, **249**
 supportive therapy, 246–247
- macroalbuminuria
 ABCD trial, 239
 ACEi risk reduction of, 235
 death rate, vs. microalbuminuria, 64
 microalbuminuria progression to, 64, 236,
 288–290
 as risk factor in CVD, 64
 in type 2 diabetes, 232, 236–237
- magnesium salts, for hyperphosphatemia,
 366–367
- maintenance immunosuppression
 tacrolimus-MM-corticosteroids for, 592–593
 without CNIs, 594–596
 without corticosteroids, 593–594
- malnutrition in dialysis patients, 433–435, **434**,
 441
- Mann, J. F. E., 46
- mannitol bicarbonate, 100–101
- marathon runners and hyponatremia, 620, 630
- MARVAL study. *See* MicroAlbuminuria Reduction with
 Valsartan (MARVAL) study
- Maryland County study, of hypertension-smoking-CKD,
 214
- mass transfer area coefficient (MTAC), 489
- MCD. *See* minimal change disease (MCD)
- MDRD Study. *See* Modification of Diet in Renal Disease
 (MDRD) Study
- mechlorethamine (nitrogen mustard therapy), 794
- mefenamic acid, 289
- MELD (Model for End-Stage Liver Disease) Score,
 93
- membranoproliferative glomerulonephritis (MPGN)
 classifications, 183–185
 clinical features/natural history, 185–187
 described, 183
 epidemiology, 812
 etiology, 810–812
 evidence base for treatment recommendations
 observational/uncontrolled studies, 190–192
 randomized controlled trials, 187–190, **812**, 813,
814
 suggested algorithms, 185
 HCV presence in, 272
 with HCV/type II cryoglobulinemia, 272–276
 pathology, 273–274
 treatment, 274–276
 from hepatitis B virus, **264**
 natural history of, 812–813
 progression to ESRD, 186
 therapies, 813–815
- membranous nephropathy. *See* idiopathic membranous
 nephropathy (MN)
- membranous nephropathy (MN)
 ACTH for, 166–167
 as cause of ESRD, 158
 clinical manifestations, 158–159
 eculizumab for, 166
 low-risk patients, treatment, 160
 mycophenolate mofetil for, 164–165
 natural history, 158
 predicting factors, 159
 response measurements, 159
 treatment, 160–162
- mercury (environmental nephrotoxin), 296

Index

- metabolic acidosis
causes/contributory factors/consequences, 432, 612–613, **613**
correction of, 432–433
description, 612–613
redistribution hyperkalemia from, 634
treatment, 613–614
- metabolic alkalosis, 615, **615**
- metabolic bone disease, from CKD, 3
- metabolic syndrome
and cardiovascular disease, 234
control of, for slowing disease progression, 317
- metal salt phosphate binders (for hyperphosphatemia)
aluminum salts, 365
lanthanum-carbonate, 365–366
- metastatic infections related to hemodialysis (HD), 442, 443
- methicillin, as cause of AIN, 122, 125
- methotrexate, as cause of crystalline nephropathies, 127
- methylprednisolone. *See also* pulse methylprednisolone therapy (PMT), for pediatric SRNS
for HCV-related glomerulonephritis nephritis, **275**
high-dose IV, for first acute rejection episode, 576
high-dose vs. low-dose pulses, 190
for idiopathic MN, 167
for IgA nephropathy/rapid unexplained GFR decline, 172
with IV cyclophosphamide pulses for lupus nephritis, 247
for membranous nephropathy, 161
for MPGN, 185, 193, **813, 814**
for steroid-resistant nephrotic syndrome, 797, **798**
vs. CsA, 810, **811**
vs. deflazacort, 707
- metoprolol
for hypertension, 209
vs. ramipril, 351
- microalbuminuria, 8
ACE inhibitors for, 240
death rate, vs. macroalbuminuria, 64
defined, 8
evaluation of living donors, 551
insulin resistance in, 234
during pregnancy, 301
progression to macroalbuminuria, 64, 236
risks for African Americans, 551
in type 2 diabetes, 232
- MicroAlbuminuria Reduction with Valsartan (MARVAL) study, 238
- microscopic hematuria, **133, 313**
in adult IgAN, 170
in children with MCD histology, 765
in HBV-associated MPGN, 265
in HCV-associated MPGN, 273
Japanese study, 552
in membranous nephropathy, 159
recommendations for adults/children, 175
- midodrine, for HRS, 88, 91, 92–93
- mineral and bone disorder (MBD) of CKD/ESRD
bisphosphonates, 375–376
calcimimetic therapy, 374–375
defined, 355–356
guidelines/recommendations, **354**
hyper-/hypoparathyroidism, 373–374
hyperphosphatemia (*See* hyperphosphatemia)
KDIGO guidelines, 355
onset determination, 356
Veterans Affairs retrospective cohort study, 360–361
vitamin D deficiency, 355
defined/epidemiology, 356–357
1,25(OH)₂-vitamin D₃, 356, 358
outcome determinations, 358–359
preparation evaluations, 355
supplementation for, 357–358
PTH end-treatment reduction levels, 359
25(OH)-vitamin D deficiency, 357, 359–360
- minimal change disease (MCD)
defined, 149
HCV presence in, 272
natural history
adulthood presentation, 150, **152**
elderly presentation, 150–151
progression to ESRD, 150
treatment recommendations, **152**
alkylating agents, 151
corticosteroids, 151
CsA, 151
mycophenolate mofetil, 151
- minimal change disease (MCD)-induced SRNS, 787, 792
- minimal change glomerulopathy, 123
- minocycline, 444, **464**
- mixed IgG/IgM cryoglobulinemia (type II cryoglobulinemia), 183
- mizoribine
for IgAN, in adults and children, 179
for pediatric steroid-resistant nephrotic syndrome, 792
vs. placebo, **781**
- MMF. *See* mycophenolate mofetil (MMF)
- Modification of Diet in Renal Disease (MDRD) Study, 4, 29, 31, 34, 347
accuracy in CKD, 208
blood pressure level recommendations, 216
fluid intake data, 317
in lupus nephritis, 244
in membranous nephropathy, 160
performance analysis, **59**
performance vs. Cockcroft-Gault equation, 59
monoclonal (OKT3) antibodies, 575, 576, 577
- MPGN. *See* membranoproliferative glomerulonephritis (MPGN)
- MRFIT study (Multiple Risk Factor Intervention Trial), 45, 49
- mTOR inhibitors, 603, 604. *See also* everolimus (EVL); sirolimus (SRL)
- Multicentre Investigation of Icodextrin in Ambulatory Peritoneal Dialysis Study (MIDAS), 503–504
- multiple myeloma (MM) associated with AKI, 126–127
causes of, 126–127
definitions/etiology, 126
survival rates, 127
- Multiple Risk Factor Intervention Trial (U.S.), 214
- mupirocin ointment, 444, 445, 465, 512
- muromonab, monoclonal antibody, 577
- mycophenolate mofetil (MMF)
for CAN secondary prevention, 603
with CsA corticosteroids, 593
discontinuance during pregnancy, 305
for FSGS, 153
for IgAN in adults/children, 179
and immunosuppression maintenance, 706–707
for immunosuppression maintenance, 592–593
for lupus nephritis, 248–249
for MCD, 151
for membranous nephropathy, 164–165
for MPGN, 191
for pediatric steroid-resistant nephrotic syndrome, 792
for PVAN, 280
for relapsing nephrotic syndrome, 781
use of during pregnancy, 155
- N-acetylcysteine (NAC), 484
for contrast-induced nephropathy, 115
for prevention of ATN, 103–104
protective effects from contrast-associated nephropathy, 35, 138, 143
- National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, 435
- National Cooperative Dialysis Study (NCDS), 424, 427–428, 738, 739
- National Health and Nutrition Survey III (NHANES III), 7–8, 24, 43–44, 294
- National High Blood Pressure Education Program, 306, 669
- National Institute of Diabetes and Digestive and Kidney Diseases, 18
- National Institute of Health and Clinical Excellence, 219
- National Institutes of Health (NIH), 247, 643
- National Kidney Foundation (NKF)
CKD staging definitions, 5
hypertension/BP guidelines, 347
Kidney Early Evaluation Program (KEEP), 18
recommendation of ARBs/ACEi, 35
staging classification proposal for CKD, 43
Task Force on Reuse of Dialyzers, 456
- National Kidney Foundation of Singapore Screening Program, 25–26
- National Transplantation Pregnancy Registry, 305
- Native Americans, diabetes/diabetic nephropathy risks, 49, 233, 234
- natriuretic peptides. *See also* atrial natriuretic peptides; brain natriuretic peptide (BNP)
brain natriuretic peptide (BNP) (*See* brain natriuretic peptide)
for cardiorenal syndrome, 84
for prevention of ATN, 105
- NECOSAD. *See* Netherlands Cooperative Study on the Adequacy of Dialysis
- neoplasias, 158, 709
- nephrolithiasis, 85, 207, **546, 552**
living donor evaluation, **546, 553**
obesity association, 554
- nephron underdosing hypothesis (Brenner), 207
- nephrotoxicity
from adefovir dipivoxil, 266
from aminoglycosides, 97–98, 525
from calcineurin inhibitors, 563, 706, 766

- in chronic allograft nephropathy, 601
 from chronic CNI administration, 594, 595, 599, 601–604
 in CsA therapy, 151, 162, 788
 in diabetes mellitus, 236
 drug-induced, in HIV-1 infection, 258
 from IFN therapy, 266
 from NSAIDs, 290, 318
 from phenyl/methoxy methyl mercuric salts, 296
 radiocontrast nephrotoxicity, 224
 from tenofovir, 259
 nesiritide (synthetic BNP), 84
 Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD), 403–404
 neutral pH, bicarbonate (\pm lactate)-buffered, low-GDP fluids, 502–503
 neutral pH, lactate-buffered, low-GDP fluids, 501–502
 neutrophil gelatinase-associated lipocalin (NGAL), 75, 76
 NGAL. *See* neutrophil gelatinase-associated lipocalin (NGAL)
 nifedipine, 189, 238, 305, 642
 nitrogen mustard therapy (mechlorethamine), 794
 nocturnal enuresis in children, 753–755
 alarm vs. control, 755
 assessment and investigation, 753
 desmopressin
 vs. alarm, 757
 vs. placebo, 756
 epidemiology, 753
 evidence ratings/treatment recommendations, 754
 management, 753–755
 risk factors, 753
 nocturnal intermittent peritoneal dialysis (NIPD), 478, 482
 nondihydropyridine calcium channel blockers (NDHCCBs)
 for slowing progression of disease, 316 (*See also* diltiazem; verapamil)
 for type 2 diabetes, 231, 238
 non-metal-based phosphate binders (for hyperphosphatemia)
 calcium carbonate/calcium acetate, 367
 magnesium salts, 366–367
 nonpharmacological therapy
 for HRS, 93–94
 dialysis, 93–94
 liver transplantation, 93
 TIPS, 93
 for hypertensive CKD, 216
 for pediatric CKD, 699
 for pediatric hypertension, 670
 for persistent/increasing proteinuria, 347
 nonsteroidal anti-inflammatory drugs (NSAIDs). *See also* COX-1 cyclooxygenases; COX-2 cyclooxygenases; COX-2 mRNA/inducible COX-2 mRNA; individual drugs
 as cause of AIN, 122, 125
 discontinuation, in cast nephropathy, 127
 effects on renal prostaglandins, 287
 gastrointestinal/renal side effects, 286
 inhibition of renin secretion, 288
 membranous nephropathy association, 158
 for MPGN, 191
 postoperative use of, 287–288
 for proteinuria, 160
 proteinuria reduction from, 160, 290
 norepinephrine for hepatorenal syndrome, 88, 91, 92, 93
 Normal Hematocrit Study (U.S.), 324
 normalized protein catabolic rate (nPCR), 426
 normalized protein nitrogen appearance (nPNA), in hemodialysis patients, 435
 Norris, Christopher, 633–639
 North American Pediatric Transplant Cooperative Study (NAPRTCS), 693, 705, 726, 727
 Norway
 ESRD rates, 63
 MPGN diagnosis review, 813
 nosocomial infections in dialysis patients
 background information, 452
 bacterial infections, 453
 dialyzer reuse issues, 455–456
 epidemiology of, 452
 guidelines/recommendations
 dialyzer reuse reprocessing issue, 457–458
 immunizations, 456
 isolation, 456–457
 water control, 457
 pathogenesis of, 453
 viral infections, 453–454
 water quality issues, 454, 454
 nucleotide reverse transcriptase inhibitors (NRTIs), 259
 nystatin, 511, 513, 516, 529
 obesity
 albuminuria elevation in, 217
 Asian susceptibility to, 220
 as CKD development marker, 30, 49, 214, 317
 contraindication for dialysis, 395
 evidence/recommendations for transplantation, 541
 FSG and, 36
 glucocorticoid-associated/whole body BMC, 687
 living donor evaluation, 554
 low HDL/high triglyceride association, 339
 pediatric carotid IMT and, 672
 puberty/posttransplantation, 656
 as side effect of steroid therapy, 190
 as stone formation risk, 642–644, 648
 type 2 diabetes and, 231
 obstructive nephropathy, 81, 82, 84–85
 octreotide, 92, 93, 93
 Okinawa (Japan) Screening Program, 24–25
 olmesartan, 35
 1,25(OH)₂-vitamin D₃. *See* vitamin D
 Organ Procurement and Transplantation Network (OPTN), 18, 546–547
 orniopressin, 91
 orthostatic hypotension, 80, 85, 279–280
 ostial stenoses, 226–227
 PAN. *See* polyarteritis nodosa (PAN)
 PAOP. *See* pulmonary artery occlusion pressure (PAOP)
 paracetamol, 289
 parenchymal renal disease, 202
 paricalcitol. *See* vitamin D
 PD capacity (PDC) program, 489
 pediatric anemia
 causes of, 693
 definitions/guidelines, 693–694
 evaluation recommendations, 694
 K/DOQI guidelines, 693–694, 699
 sequelae
 cardiac function, 696
 QoL and cognitive function, 695–696
 risk of CKD progression, 695
 risk of death, 694–695
 treatment, 696–699
 ESAs, 696, 697, 698
 iron agents, 696, 699
 pediatric chronic kidney disease (CKD). *See also* left ventricular mass (LVM) in children with hypertension/CVD
 childhood phase, 655
 glucocorticoid induced osteoporosis, 685–687
 prenatal/infantile phases, 655
 pubertal phase, 655
 pediatric daytime urinary incontinence, 755, 757–759
 assessment, 757–758
 epidemiology, 755
 evidence rating/treatment ratings, 758
 management, 758–759
 natural history, 757
 prevalence, 755, 757
 risk factors, 757
 pediatric dyslipidemia in CKD
 in pediatric patients, 673–678
 evidence ratings/recommendations, 675
 lifestyle modifications, 674
 statin therapy, 674–675
 prevention/treatment strategies, 673–678
 evidence ratings/recommendations, 675
 lifestyle modifications, 674
 statin therapy, 674–675
 pediatric edema, 770
 pediatric hemodialysis, 738–743
 adequacy
 background and definition, 739
 pediatric-specific issues, 739–741
 catheter/patient size guidelines, 742
 evidence ratings/recommendations, 742
 evidence table, 743
 HEMO study, 739–740
 K/DOQI guidelines, 740
 nutrition management, 742
 physiology of (pediatric issues), 738–739
 target dry weight assessment/UF management
 noninvasive monitoring (NIVM) of hematocrit, 741
 sodium modeling, 741
 vascular access, 742–743
 pediatric hypertension/CVD in CKD, 670–673
 blood pressure measurements, 669–670
 ABPM, 669–670
 home monitoring, 670
 carotid artery intima media thickness (IMT), 672
 C-reactive protein levels, 672
 Fourth Report recommendations, 671
 left ventricular mass (LVM), 670–672
 National High BP Education Program, 669, 670
 prevention/treatment strategies, 670, 672–673
 ACEi/ARBs, 670, 672
 evidence ratings/recommendations, 671, 674

Index

- pediatric Immunoglobulin A nephropathy (IgAN)
 comorbidities
 isolated microscopic hematuria and proteinuria, 175
 with nephrotic syndrome, 176
 with rapidly declining GFR, 175–176
 with recurrent microscopic hematuria, 174–175
 with slowly progressing renal impairment, 176–177
 COOPERATE study, 174
 evidence, 174
 immunosuppressive treatments
 corticosteroids, 177
 cyclophosphamide with/without azathioprine, 178–179
 MMF and mizoribine, 179
 natural history, 171
 recommendations, 173, 174
 pediatric kidney transplantation
 epidemiology/outcomes/management
 of chronic rejection/allograft nephropathy, 707
 of disease recurrence, 708
 hemolytic uremic syndrome, 709
 MPGN, 709
 steroid-resistant nephrotic syndrome, 708–709
 of infectious diseases
 CMV infections, 707
 fungal diseases, 708
 other viruses, 707–708
 of malignancy, 709
 for patient/graft
 donor/recipient factors, 705
 graft function estimation, 705
 long-term, 704
 recipient factors, 705
 short-/middle-term, 703–704
 survival rates/causes of death, **704**
 treatment adherence, 709
 evidence ratings/recommendations for interventions, **717–718**
 French and North American reports, **704**
 immunosuppression regimens
 induction therapy, 705–706
 maintenance immunosuppression, 706–707
 summary of studies, **710–717**
 pediatric nocturnal enuresis, 753–755
 pediatric peritoneal dialysis (PD), 723–734
 adequacy of dialysis, 731–734
 amino acid dialysate, 732
 bicarbonate-buffered vs. lactate buffered dialysate, 732
 CCPD/NIPD CAPD tidal PD, 734
 fill volume, Kt/V, creatinine clearance, 732–733
 icodextrin, 732
 associated infections
 available evidence, 730
 epidemiology, 727, 730
 guidelines, 730
 peritonitis/catheter-related, **728–729**, 730, 730
 preventive antibiotic interventions, 730–731
 technique-related preventive strategies, 731
 catheter use/placement
 available evidence, 726
 clinical implications, 727
 guidelines, 726
 clinical implications with RRT choice, 726
 comorbidities, 726
 evidence ratings/recommendations, **733**
 hospitalization, 726
 patient survival/causes of death
 causes of death, 725–726
 determinants, 723
 PD vs. HD., 723, 725
 technique survival, 726
 pediatric renal osteodystrophy, 355, 358, 682–689
 bone histomorphometry of, 682, **683**
 bone mineral density (BMD), 685–687
 DXA classification of bone health, 687–689
 evidence ratings/recommendations for interventions, **688**
 glucocorticoid-induced osteoporosis, 685–687
 PTH assays/bone turnover, 682–683
 QCT assessment of bone status, 689
 treatment of, 682, 684–685, **684**, **686**
 pediatric steroid-resistant nephrotic syndrome (SRNS), 654–655. *See also* minimal change disease (MCD)-induced SRNS
 available evidence, 767–768
 causes, **764**
 definitions, 764, **765**
 edema, 770
 epidemiology, 763–764
 evidence-based recommendations, 770
 indications, 764–765
 lipid level management, 674
 long-term outcomes, 766–767
 management of infections
 Chinese herbal preparations, 768
 influenza vaccinations, 768
 IVIG, 768
 pneumococcal vaccinations, 767
 prophylactic antibiotics, 768
 strategies for varicella-zoster, 768
 thymosin, 768
 posttransplantation treatment challenges, 708–709
 relapses, 766
 secondary resistance, 765–766
 thrombosis, 768–770, **769**
 pediatric steroid-resistant nephrotic syndrome (SRNS), treatments
 alkylating agents
 intravenous CPA, 794, **796**
 oral CPA, 792–794, **795**
 antibody therapy/rituximab (anti-CD20), 801
 bone marrow transplantation, 801
 calcineurin inhibitor therapy, 766
 cyclosporine, 787–788
 tacrolimus, 788
 combination therapy, 794–797
 calcineurin inhibitors + MMF, 797
 PMT/alternate-day oral corticosteroids/CPA, 797
 PMT + CsA, 797
 PMT + heparin, 797
 PMT/IV immunoglobulin/statin, 797
 corticosteroid therapy
 oral corticosteroids, 788, 792
 short course/high dose pulse intravenous, 792
 nonimmunosuppressant therapy
 ACEi, 797
 statin therapy, 797
 pheresis-based therapies, 801
 purine synthesis inhibitors
 azathioprine, 792
 mizoribine, 792
 mycophenolate mofetil, 792
 remission/intervention ratings and recommendations, **788**
 vincristine/nitrogen mustard therapy (mechlorethamine), 794
 pediatric steroid-sensitive nephrotic syndrome (SSNS), 654–655, 663, 686–687, 774–784. *See also* frequently relapsing nephrotic syndrome
 corticosteroid-sparing agents
 alkylating agents, 779
 cyclosporine, 780
 levamisole, 780–781
 mycophenolate mofetil, 781
 tacrolimus, 781
 corticosteroid treatment, 774–777, 777
 prednisone trial, 775
 pediatric thrombosis, 768–770
 pediatric urinary tract infections (UTIs)
 acute treatment, 747–749
 clinical presentation, 746
 diagnosis, 746–747
 epidemiology, 747
 evaluation/imaging of renal tract, 750
 pathogenesis, 747
 recurrence/recurrence prevention, 747, 749–750
 pediatric vesicoureteric reflux, 751–753
 clinical spectrum, 751
 definition and diagnosis, 751
 epidemiology, 751
 as inherited trait, 751
 management, 751–753
 prognosis, 751
 screening, 751
 pegylated interferon (PEG IFN), 266, 539
 D-penicillamine, 158, 649, **764**
 peripheral vascular disease
 evidence/recommendations for transplantation, 537
 pretransplantation screening for, 567
 septicemia in ESRD association, 453
 peritoneal dialysis, 137. *See also* automated peritoneal dialysis (APD); continuous ambulatory peritoneal dialysis (CAPD); nocturnal intermittent peritoneal dialysis (NIPD); pediatric peritoneal dialysis
 access planning for, 396–397
 for ESRD, 12
 European Best Practice Guidelines, 403
 hemodialysis vs., as RRT, 471, **472**
 medical factors for selection for RRT
 patient survival, 472–473
 quality of life/socio-economic considerations, 473
 mortality risks from, 393, 395
 CANUSA study, 404
 USRDS study, 404–405
 vs, hemodialysis therapy, **363**, **406**
 negatives-positives of, 404–407
 nonmedical factors for selection for RRT, 471–472
 patient counseling for, 393–394
 preparation timeline, 397

- small solute clearance in, 478–484
- special patient groups
- anuric patients, 473
 - cardiac patients, 474
 - diabetics, 473
 - elderly patients, 474
 - large/heavy patients, 474
 - before transplantation/in failed transplant patients, 474–475
- peritoneal dialysis, salt and water balance, 488–495
- augmentation measures
- dietary intake, 492–493
 - hyperglycemia control, 493
 - increased urinary excretion, 493
 - membrane function preservation, 493, 494
 - salt removal by PD, 493
- automated PD vs. CAPD, **493**
- biocompatible PD solution trials, **495**
- catheter problems, 491
- influence of removal, 488
- intrapertoneal agents effects on peritoneal transport, **494**
- low-sodium solution, effects of, **494**
- tests of peritoneal transport
- accelerated peritoneal examination (APEX), 489
 - dialysis adequacy and transport test (DAT), 489
 - fast PET, 489
 - frequency/timing of, 490
 - PD capacity (PDC) program, 489
 - pediatric patients, 490
 - peritoneal equilibration test (PET), 488, **489, 491**
 - peritoneal function test (PFT), 489
 - short PET, 489
 - standard peritoneal permeability analysis (SPA), 489
- ultrafiltration failure (classification, diagnosis, management)
- catheter problems, 491
 - dialysate leaks, 490
 - effects of icodextrin PD solution, **494**
 - low drain volume/high-low average transport
 - aquaporin deficiency, 492
 - lymphatic reabsorption/tissue reabsorption, 492
 - mechanical problems, 492
 - low drain volume/high transport
 - high transport during long-term PD, 492
 - inherent high transport, 491
 - recent peritonitis-inherent high transport, 491–492
 - low drain volume/low transport, 492
 - peritoneal function evaluation, 491
- peritoneal dialysis, small solute clearance, 478–484
- ADEMEX trial, 479, 480
 - assessment of, 478–480
 - CANUSA data reanalysis, 479
 - CAPD and, 479–480
 - K/DOQI guidelines, 478–480
 - Kt/V_{urea} and, 478, 479, 480, 482
 - lack of survival benefit with, 479
 - optimization strategies, 480–482
 - residual renal function
 - aminoglycoside assessments, **483**
 - impact on patient survival, 478, 479
 - preservation strategies, 482–484
 - RRF preservation strategies, 482–484
- survival studies, **481, 482**
- target recommendations/adequacy monitoring, 480, **484**
- peritoneal dialysis-related infections
- available evidence for prevention of
 - antimicrobial agents, 512, **513, 516–517, 517, 520–521**
 - catheter-related interventions, **518, 522–523**
 - BRA/CARI guidelines, 511, 512
 - effects of interventions, **519**
 - exit site/tunnel infections (*see* exit site and tunnel infections)
 - in pediatric patients, 727–731
 - peritonitis (*see* peritonitis)
 - randomized controlled trials
 - of antimicrobial agents, **513**
 - of catheter-related interventions, **514**
 - characteristics of interventions/populations, **515–516**
- peritoneal dialysis solutions
- impact on outcomes, 500–505
 - amino-acid dialysates, 504–506, **505**
 - icodextrin, 503–504
 - neutral pH, bicarbonate (± lactate)-buffered, low-GDP fluids, 502–503
 - neutral pH, lactate-buffered, low-GDP fluids, 501–502
 - intervention/population characteristics in RCTs, **501**
 - MIDAS study, 503–504
- peritoneal equilibration test (PET), 488, **489**
- peritoneal function test (PFT), 489
- peritonitis, 510
- consequences of, 509
 - diagnosis of
 - abdominal pain, 510–511
 - cloudy effluent, 510
 - grain stain and culture, 511
 - incidence statistics, 509
 - prevention of
 - antimicrobial agents, 512, **513, 516–517, 517, 520–521**
 - catheter-related interventions, **518, 521, 522–523**
 - exit site infections, 511
 - treatment of, 511–512, 516, 524–529
 - aminoglycosides in PD patients, 483–484
 - CARI recommendations, 525
 - cephalosporin, 525, 525
 - cephazolin, 483, 524
 - double bag vs. Y-systems, 523
 - effect of oral antibiotics, 520
 - intermittent vs. continuous intraperitoneal antibiotics, 527
 - intrapertoneal ciprofloxacin-rifampin, 525
 - intrapertoneal vs. oral antibiotics, 526
 - IV antibiotic prophylaxis, 521
 - nasal antibiotics, 520
 - netilmicin, 483
 - ratings/recommendations for interventions, **528**
 - urokinase vs. catheter removal, 527
 - Y-set vs. spike catheters, 522
- phenylbutazone, 123, 289
- phosphate binders
- for hyperphosphatemia, **364**
 - metal salt
 - aluminum salts, 365
 - lanthanum-carbonate, 365–366
 - non-metal-based
 - calcium carbonate/calcium acetate, 367
 - magnesium salts, 366–367
 - for pediatric renal osteodystrophy, 684–685, **684**
- phospholipase A₂, 286
- plasma cell dyscrasias, 126, 127
- plasmapheresis
- causative for hypokalemia, **638**
 - for HCV-related cryoglobulinemic MPGN, 275
 - limited success in HIV-associated TMA, 258
 - in MPGN with type II cryoglobulinemia, 275
 - supportive for immunosuppressive therapy, 809
 - for treatment of nephrotic FSGS, 155
 - vs. protein adsorption, in renal transplantation, 708
 - with/without IVIG for rejection, 576, 603
- platinum silver, 444
- polyarteritis nodosa (PAN), 263, **264, 267, 273**
- polyclonal (ALG/ATG) antibodies, 575, 576
- polycystic kidney disease (PKD), 203
- benefit/detriment of ACEi, 220
 - GFR decline association, 317
 - living donor evaluation, 553
 - during pregnancy, 302–303
 - as stone-associated condition, 643
- polyomavirus-associated nephropathy (PVAN)
- BK virus (BKV) association in, 277–282
 - screening for, **282**
 - challenges/definitions of, 277
 - definitions, 277, **278**
 - diagnosis, 279
 - management in kidney transplant patients, 278
 - pathogenesis of, 278
 - retransplantation after renal allograft loss due to, 280, 282
 - risk factors, 278–279
 - screening for PVAN BKV replication, **278, 279**
 - treatment
 - antiviral approaches, 280, **2811**
 - BKV screening/early intervention, 280, **282**
 - reduction of immunosuppression, 280
- postobstructive diuresis, 85
- posttransplant lymphoproliferative disease (PTLD), 706
- potassium (K⁺)
- disorders of (*See* hyperkalemia; hypokalemia; hypomagnesemia)
 - factors affecting concentrations, **634**
 - intravenous replacement of, 638
 - mechanisms of distribution, 633
 - oral replacement of, 638
- potassium (K⁺) disorders. *See* hyperkalemia; hypokalemia
- potassium (K⁺) sparing diuretics, 639
- povidone-iodine (topical antiseptic), 444, 516
- practice-based screening/quality management (for CKD), 26–27
- pravastatin, 336, 338
- Pravastatin Pooling Project, 336

Index

- prednisolone
 for children, with calcium plus vitamin D treatment, 687
 deflazacort derivation from, 663
 for diffuse proliferative lupus nephritis, 248
 evaluation for pediatric proteinuria, 178
 for FSGS, **154**
 high-dose IV, for first acute rejection episode, 576
 for idiopathic membranous nephropathy, 161, **163**
 for IgA nephropathy/rapid unexplained GFR decline, 172
 for MCD in adults, 151, **152**
 for MPGN, 185
 remission for children with idiopathic nephrotic syndrome, 763
- prednisone
 aggravating for hypertension, 188
 alternate-day therapy, MPGN evaluation, 188
 for children
 alkylating agents in SSNS, **779**
 alternate-day therapy, 774
 CPA vs. prednisone, 792
 with frequently relapsing SSNS, **783**
 with hematuria/proteinuria, 177
 with IgAN, 178, 179
 initial episode of SSNS, **775**, 776, 778, 782
 with rapidly declining GFR, 175
 with relapsing SSNS, **781**
 treatment duration, 657
 for class III/IV lupus nephritis, **247**
 with CsA for steroid-resistant MN, 162
 for HIV-associated glomerulonephritis, 258
 for HIV-associated TMA, 258
 for HSP, 807, 808–810, **811**
 for idiopathic membranous nephropathy, 161, **163**, 165
 for IgA nephropathy, 171, 172
 for initial episode of SSNS, **775**
 with IV cyclophosphamide pluses, 247
 for MPGN, 185, **812**, **813**
 for pediatric IgAN, 177
 for pregnancy-related transplantation, 305
 vs. prednisolone, for MCD, 151
 withdrawal trials, 593
- preeclampsia
 dopamine's performance for, 105
 hypertension and, **202**
 during pregnancy, 299–306
- pregnancy
 cyclosporine A us, 155
 ESRD therapy during
 dialysis, 304–305
 transplantation, 305
 hypertensive disorders, 305–306
 kidney disease in
 acute fatty liver, 304
 acute tubular necrosis, 304
 chronic glomerulonephritis, 302
 chronic kidney disease, 301
 chronic pyelonephritis, 303
 developed during pregnancy, 303
 first time diagnosis, 303
 polycystic kidney disease, 302
 with systemic illness, 301–302
 thrombotic microangiopathy, 303–304
 urinary tract obstruction, 304
 mycophenolate mofetil use, 155
 preeclampsia during, 299–306
 renal anatomy/physiology in
 acid-base regulation, 300
 blood pressure regulation, 300
 hemodynamics, 299–300
 urinary tract, 299
 volume regulation, 300
 water metabolism, 300
 renal function assessment in, 300–301
 steroid therapy complications, 305
 pre-renal failure. *See also* acute tubular necrosis (ATN);
 cardiorenal syndrome; obstructive
 nephropathy
 causes of, **81**
 characterizations of, 80
 diagnosis of, 80–82
 CVP/PAOP, 81
 urinalysis, 81–82
 urinary indices, 82
 urine output, 81
 treatment of, 82–83
 crystalloid vs. colloid fluids, 83
 hemodynamic management/fluid therapy, 82–83
 IV albumin, 90
 pretransplantation cardiac screening, 567–568
 PREVEND study (Prevention of Renal and Vascular
 End-Stage Renal Disease study), 45, 64, 103,
 218
 Preventive Services Task Force (U.S.), 538
 primary hyperparathyroidism, 373, 643, 646, 688
 Program to Improve Care in Acute Renal Disease, 97, 138
 progression of kidney diseases
 assessments
 albuminuria/proteinuria quantification, 2
 GFR measurement, 29–30, **31**
 renal resistance index, 30
 confounding effect of cardiovascular prognosis, 29
 etiology as determinant, 29
 monitoring of
 GFR trends, 312–313
 proteinuria trends, 312
 risk factors, 29, **30**
 treatment strategies for delay/prevention
 aldosterone antagonists, 317
 beta blockers, 317
 blood pressure control, 313, 314, 315
 blood pressure lowering, 31–33
 correction of severe anemia, 318
 dihydropyridine CCB avoidance, 316
 diuretic therapy, 316–317
 herbal therapy, avoidance of, 318
 hyperphosphatemia/hyperparathyroidism control,
 318
 metabolic syndrome control, 317
 NAHCO₃, 318
 NDHCCB therapy, 317
 NSAIDs avoidance, 318
 obesity, 36
 protein intake control, 37, 344
 RAAS blockade, 35–36
 reduction of proteinuria, 33–34
 renin inhibition, 318
 restriction of salt intake, 37, 316–317
 smoking, 36
 smoking cessation, 318
 uric acid level control, 318
 water intake control, 37, 345
 protein nitrogen appearance (PNA), in hemodialysis
 patients, 435
 proteinuria. *See also* MRFIT study; unremitting
 nephrotic-range proteinuria
 ACEi/ARBs for, 160, 219, 797
 in acute tubulo-interstitial nephritis, 288
 adults vs. children, 149
 assessment of
 threshold values, 61
 timed vs. untimed urine sample, 61
 vs. albuminuria, 61
 Bence-Jones proteinuria, 127
 blood pressure association, 313, 316, 318, 345–349, 351
 body mass index (BMI) and, 26, 36
 in childhood idiopathic nephrotic syndrome, 763, **765**,
 766–767
 in chronic allograft nephropathy, 600–602, 604–605
 creatinine clearance measurement for, 111
 in diabetes mellitus, 231, 233, 235–239
 dyslipidemia and, 333–334, 337, 338
 effects of BP goal/selection of antihypertensive agents,
 210
 ESRD association with, 45
 in essential hypertension, 207–210, 214–220, 672, 673
 in children, **671**
 in FSGS, 149, 152, 155
 in HCV-associated MPGN, 273
 in hepatitis B, 264–266
 in hepatitis C, 273, 275
 HIV-1 levels, 253
 and HIVAN/collapsing glomerulopathy, 253–254
 in IgA nephropathy, 170–179
 increase of with smoking, 36
 in infection-related nephropathies, 253–255, 257–260
 lipid abnormalities associated with, 160
 living donor evaluation, 550–551, **550**
 lowering, as CKD treatment strategy, 33–35
 in lupus nephritis, 244, 246–250
 magnitude/risk of natural progression, 311
 as marker for diabetic/nondiabetic kidney disease, 217
 in MCD, 149
 in membranous nephropathy, 158–167
 monitoring of trends, 312
 in MPGN, 185–193, **812**
 NSAIDs for, 160, 290
 obesity association, 317
 during pregnancy, 301–303, 305
 progression of CKD by degree of, **44**
 quantification of, 30
 ramipril for lowering, 346
 RAS blockade for minimization of, 173
 renoprotectiveness of decrease, 231
 and risk for ESRD/CV outcomes, 63–64
 role in promoting kidney disease/diabetic
 nephropathy, 209
 in steroid-resistance nephrotic syndrome, 787, **793**,
795, **796**
 transplantation issues, 709, **713–714**, **716**
 pseudohyperkalemia, 633, **634**

- Pseudomonas aeruginosa*, 443, 511–512
 psychogenic polydipsia, 618, 619–620, 622, 629
 psychological evaluation, of living donors, 553
 pulmonary artery occlusion pressure (PAOP), 81
 pulse methylprednisolone therapy (PMT), for pediatric SRNS, 792, 796, 797, 798, 801
 purine synthesis inhibitors, 792
 PVAN. *See* polyomavirus-associated nephropathy (PVAN)
- quality of life (QoL) and socio-economic considerations, for PD selection, 473
 Quality of Reporting of Meta-analyses (QUOROM) criteria, 703
- RAAS blockade. *See* renin-angiotensin-aldosterone system (RAAS) blockade
 race. *See also* African Americans; Asian cultures; Caucasians; Hispanics
 as CKD risk factor, 9–10, 48–49
 and type 2 diabetes, 231, 233
 radiocontrast nephropathy. *See* contrast-induced nephropathy (CIN)
 ramipril, 174, 216, 218, 347
 for decline in residual renal function, 493
 ESCAPE trial, 673
 for lowering proteinuria/ESRD progression, 346
 for nondiabetic kidney disease, 238
 with RAAS blockade, 34
 vs. amlodipine, 220, 351
 vs. beta-blockers, 216
 vs. metoprolol, 351
 Ramipril Efficacy in Nephropathy 2 (REIN-2) study, 216, 238, 346
 Rapamune Maintenance Regimen Trial, 594, 595
 RAS blockade. *See* renin-angiotensin system (RAS) blockade
 rasburicase, for hypouricemic therapy, 131
 reactive oxidative species (ROS) production
 as CAN mediator, 601
 recombinant human growth hormone (rhGH), 661, 705
 recurrent disease patients
 evidence/recommendations for transplantation, 540–541
 recurrent peritonitis, 510
 redistribution hyperkalemia, 634
 Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study, 32, 234, 238, 346
 reflux nephropathy, 202
 during pregnancy, 303
 refractory peritonitis, 510
 REGARDS cohort study, 49
 REIN study, 34, 347, 379
 rejection. *See* graft rejection, kidney transplantation
 relapsing peritonitis, 510
 RENAAL study. *See* Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study
 renal artery stenosis
 correction of vs. drug treatment, 226
 pathophysiology of, 223
 patient screening/screening methods, 223–224
 quantification/functional relevance estimation, 224–225
 renoparenchymatous disease exclusion, 225–226
 short/long term correction improvements, 226–227
 renal artery thromboses (RAT), 134
 Renal Association (UK), 412, 419
 renal damage, from hypertension
 diagnosis of, 208
 evidence for, 207–208
 prevention/treatment
 blood pressure targeting, 209–210
 RAAS blockade (specific benefit), 210–211
 Renal Data System (U.S.), 207–208, 244, 253
 Renal Health Library (2005), 723
 renal ischemia, 100.7, 311, 319, 363
 renal osteodystrophy in pediatric CKD. *See* pediatric renal osteodystrophy
 renal papillary necrosis, 289
 renal prostaglandins
 actions of, 287
 COX-2 NSAIDs effects on, 287
 diuretic/natriuretic properties of, 288
 maintenance of renal blood flow/GFR, 287
 Renal Registry Report (UK), 445
 renal replacement therapy (RRT), 3
 for acute renal failure (ARF), 71
 for acute tubular necrosis, 98
 cholesterol embolism/radiocontrast toxicity, 227
 for crystalline nephropathies, 128
 low-dose dopamine effect on need for, 103
 malnutrition association with, 441
 modalities/selection of, 393–395
 patient preparation for, 393
 for pediatric patients, 723
 peritoneal dialysis selection as, 471–475
 preparation for, 391
 prophylactic, for CIN, 115, 118
 selection of patients to, 10
 survival after initiation, 13
 yearly incidence of patients, 10
 renal replacement therapy (RRT), extracorporeal
 modality principles. *See also* acetate-free biofiltration (AFB); hemodiafiltration (HDF); hemodialysis (HD) therapy; peritoneal dialysis
 clinical practice guidelines review
 biocompatibility, 412
 membrane flux, 412
 RRT modality, 412
 comparison of modalities
 AFB vs. HD, 418
 AFB vs. HDF, 418
 HDF vs. HD, 418
 HF vs. HD, 418
 HF vs. HDF, 418
 evidence from review of RCTs
 biocompatibility
 β -microglobulin, 414
 dialysis-associated symptoms, 414
 hypotension, 413–414
 infection, 414
 mortality, 414–415
 protein catabolic rate, 414
 serum albumin, 414
 membrane flux
 β -microglobulin complications, 415–416
 lipid profile, 416
 mortality, 415
 quality of life, 416
 outcome expectations/membrane properties, 410–411
 procedural description, 410
 renal replacement therapy (RRT), in acute kidney injury (AKI), 137–144
 dosage of, 141–142
 mechanistic considerations
 choice of dialysate buffer for CRRT, 143–144
 hemodialyzer/hemofilter choice, 142
 use of anticoagulation, 142–143
 modality of, 139–141
 timing/initiation of, 137–139, 138
 VA/NIH ATN intensity study, 141
 renal resistance index, 30
 renal stone disease
 calcium phosphate stones, 646–647
 calcium stones, 643–644
 cystinuria, 648–649
 DASH studies, 645
 dietary recommendations, 643, 644–645, 644
 evaluation of stone formers, 643
 Kaplan-Meier estimates, 645
 medications, 645–646
 medications associated with, 643
 RCTs, 646
 struvite stones, 553, 643, 647
 uric acid stones, 647–648
 urological aspects, 642–643
 US/European guidelines, 643
 renal tubular acidosis (RTA), 296, 375, 553, 613, 638, 643, 647
 renal tubular injury, biomarkers, 75–77
 renal vein thromboses (RVT), 134
 renin-angiotensin-aldosterone system (RAAS) blockade
 for diabetic nephropathy
 ACE inhibitors, 236
 ACEi vs. ARBs, 237
 antialdosterone therapy, 237–238
 ARBs, 236–237
 renoprotective effect, 211
 for halting progression of CKD, 32, 34, 35, 36
 for hepatorenal syndrome, 88, 89, 91, 93
 for hypertension management, 209, 210–211, 215, 218–219
 renin-angiotensin system (RAS) blockade
 for children with CVD in CKD, 669, 672–673
 in diabetes mellitus, 235, 237–240
 for IgA nephropathy in adults, 173, 174, 175–177
 for proteinuria minimization in IgAN, 173, 174
 renoparenchymatous disease, 225–226
 residual renal function (RRF)
 ACEi/ARB treatment for hypertensive patients, 482–483
 cefazolin-ceftazidime vs. cefazolin-netilmicin, 483
 impact on patient survival, 478, 479
 preservation strategies for, 482–484
 rhabdomyolysis, 97, 634
 with mannitol bicarbonate, prevention of ATN from, 100–101
 prevention of ATN from, 100
 with saline resuscitation, prevention of ATN from, 100

Index

- ribavirin, 275–276
rifampin, 444, 445, **513**, **515**
RIFLE criteria
 for defining/staging ARF, 72, **72**
 for grading serum creatinine, 74, 75
 limitations of, 75
 and mortality, 74–75
 mortality and, 74–75
RIND trial cohort, 371
rituximab
 for Epstein-Barr virus, 707
 for FSGS, 152
 for idiopathic membranous nephropathy, 165–166
 for idiopathic thrombocytopenic purpura, 801
 for lupus nephritis, 249, **249**, 250
 in MPGN with type II cryoglobulinemia, 191, 275–276
ROADMAP study, 35
rofecoxib (COX-2), 286, 287, 289
RRE. *See* residual renal function (RRF)
RRT. *See* renal replacement therapy (RRT)
ruplizumab, 249–250, **249**
- salt intake
 ACEi/ARB/NDHCCB therapy and, 316
 in children with CKD, **671**
 decreasing of, as CKD treatment strategy, 37
 in membranous nephropathy, 160
 relationship to ACEi/ARB/NDHCCB therapy, 316
 stone recurrence and, 644
sarcoidosis, 122, **123**, **125**, 546, 553
Scientific Registry of Transplant Recipients (SRTR), 548
sclerosing peritonitis, 492, 509
Scribner shunt, 410
secondary hyperaldosteronism, 637, **638**
secondary hyperparathyroidism in CKD
 in animal models of renal insufficiency, 360
 calcitriol administration for management, 358
 cardiovascular mortality and, 373
 causal link with vitamin D deficiency, 353, 356
 central role in MBD development, 355
 pathogenesis, 354, 355, 356
 phosphate restriction attenuation of, 363
 treatments for, 374
 bisphosphonates, 375–376
 calcimimetic therapy, 374–375
 surgical parathyroidectomy, 374
segmental glomerulonephritis, 149, **246**, 774
sepsis, 97, 141
 acute tubular necrosis from, 97, 98, 101–102
 catheter-related, 512
 from CKD in infancy, 656
 death from, 142, 143, 767
 ESRD rates, 452
 in lactic/metabolic acidosis, 611
 in pediatric PD patients, **728**
 prevention of in thromboembolic complications,
 768–769
 rates of, in ESRD patients, 452
 sepsis-associated AKI, 140
 in urinary tract obstruction, 304
 in vascular access infections, 442, 445, **446**
septic pulmonary emboli, related to hemodialysis (HD),
442
Serratia bloodstream infections, 453
serum creatinine. *See also* Cockcroft-Gault creatinine
 clearance equation; Modification of Diet in
 Renal Disease (MDRD)
 acute kidney injury and, 72, **73**
 acute renal failure and, 71–72
 adefovir and, 266
 body mass index (BMI) association, 49
 celecoxib and, 288
 CIN and, 110, 111
 in diabetes mellitus, 234, 237
 donor issues, 548, 550, 554
 dyslipidemia in CKD and, 336, 339
 ESRD and, 548, 550
 in FSGS, **154**
 GFR association with, 4, 23, 26, 29–30, 236, 340, 575,
 658
 HIV-1 levels, 253
 in hypertension, 208, 218, 345, 346
 in IgAN, 171, 173, 174
 increase of with smoking, 36
 in infection-related nephropathies, 253, 257, **257**
 in lupus nephritis, 244–245, 248, 249
 in membranous nephropathy, 159, 161, 162, 164
 in MPGN, 186, 188, 189, **812**
 pregnancy levels, 300, 301
 in pregnant women with diabetic nephropathy,
 301
 RIFLE criteria for grading, 74, 75
 transplantation issues, 576–577, 595, **711**
 use as endogenous filtration maker, 58
 vs. cystatin C, for assessment of GFR, 74
sevelamer (for hyperphosphatemia)
 effects on bone histology, 371–372
 as substitute for statins, 338
 use as phosphate binder
 in children/adolescents, **684**
 in CKD/ESRD patients, 364t
 use determination, 372
 vs. calcium-containing phosphate binders, 684
 vs. other phosphate binders, 369–371, **370**,
 372–373
*Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation and Treatment of High
Blood Pressure*, 200
SHARP trial (of statins), 317, 336
SHEP study (Systolic Hypertension in the Elderly
Program), 46
simvastatin, 317, 336, 338, 437, 674, 797
sirrolimus (SRL)
 for CAN, 603
 for FSGS, 153, **154**
 for maintenance immunosuppression, 706
 for PVAN, 280
 for reducing immunosuppressant load, 280
small solute clearance in peritoneal dialysis,
478–484
 ADEMEX trial, 479, 480
 assessment of, 478–480
 CANUSA data reanalysis, 479
 CAPD and, 479–480
 K/DOQI guidelines, 478–480
 Kt/V_{urea} and, 478, 479, 480, 482
 lack of survival benefit with, 479
 optimization strategies, 480–482
residual renal function
 aminoglycoside assessments, **483**
 impact on patient survival, 478, 479
 preservation strategies, 482–484
 RRF preservation strategies, 482–484
 survival studies, **481**, **482**
 target recommendations/adequacy monitoring, 480,
 484
smoking
 as CAN mediator, 601
 cessation of, as CKD treatment strategy, 36, 216
 diabetic/nondiabetic CKD risks from, 220
 increase or GFR/proteinuria from, 36
Social Security Death Master File, 546
sodium bicarbonate
 in antihypertensive regimens in CKD, 314–315
 prehydration with in renovascular disease, 227
 for treatment-related acidosis, 613–615
 for urine alkalinization, 648
sodium polystyrene sulfonate (Kayexalate), 636
solvent nephropathy, 297
SPA. *See* standard peritoneal permeability analysis (SPA)
spermidine/spermine N(1)-acetyltransferase, 75
spinal epidural abscess, related to hemodialysis (HD),
442
spiral computed tomography angiography (CTA), 224
spontaneous remission
 from HBV-associated nephropathy, 264–265
 from HCV-associated MPGN, 273
 from membranous nephropathy, 158
 from minimal change disease, 150, **152**
 from nocturnal enuresis, 753
 from SSNS, 766
 uncommonness in MPGN, 190
stage 3 chronic kidney disease (CKD), **9**
stage 4 chronic kidney disease (CKD), **9**
stage 5 chronic kidney disease (CKD)
 comorbidities in, 12–13
 incidence/prevalence of, 10–11
stages 1–4 CKD, awareness patterns in treatment of, 49–51
standard Kt/V (stdKt/V), 426–427, 427
standard peritoneal permeability analysis (SPA), 489
Staphylococcus aureus
 in CKD/RRT populations, 442, 443, 445
 in PD related infections, 509, 511–512
Staphylococcus epidermidis, 443
static venous pressure (SVP), 460, 462–463
statin therapy. *See also* lipid lowering therapies;
 pravastatin; simvastatin; statin therapy
 with ACEi, for proteinuria, 160
 AURORA study, 336, 437–438
 for chronic allograft nephropathy, 604
 for HDL/LDL management, 436–437
 for high LDL, 338
 for high triglycerides/non-HDL cholesterol, 339
 mechanisms of action, 333
 for pediatric dyslipidemia, 674–675
 for pediatric SRNS, 797
 Pravastatin Pooling Project, 335
 risks from, 316
 SHARP study, 317, 437–438
 for transplant recipients with hypercholesterolemia,
 569–570, **570**
stenoses, quantification of, 224–225

Index

- steroid-resistant nephrotic syndrome, 153, 708. *See also* pediatric steroid-resistant nephrotic syndrome (SRNS)
- steroids. *See also* corticosteroids
with azathioprine for lupus nephritis, 302
with CsA, 594, 595
CsA alternative to, 152
demineralization issues, 375
for FSGS, 152–153, **154**
for HELLP syndrome, 304
for IgAN, **176**
for maintenance immunosuppression, 706
for MCD, **152**
for membranous nephropathy, 250
with MMF for proteinuria, 164
monthly cycling of, 161
pediatric use
alternate-day, 190, 661
delayed pubertal development from, 657
MGPN, 187, 189
posttransplantation withdrawal, 661, 706
SSNS, 764–765
for ureteral stone passage, 642
vs. azathioprine/cyclophosphamide, 248–249
withdrawal issues, 265
- steroid-sensitive nephrotic syndrome (SSNS) in children.
See pediatric steroid-resistant nephrotic syndrome (SRNS)
- struvite stones, 553, 643, 647
- Studies of Left Ventricular Dysfunction Trial, 83
- Study of Heart and Renal Protection (SHARP) study, 437–438
- surveillance/surveillance systems
ANZDATA, 21
British Columbia Renal Agency, 24–25
Canadian Organ Replacement Register, 21
for CKD stages 1–4, 23
defined, 18
development factors, 43–45
DOPPS, 21–23
ERA-ERDTA, 21
KEEP, 23–24
National Kidney Foundation of Singapore Screening Program, 25–26
Okinawa (Japan) Screening program, 24–25
US Renal Data Systems (USRDS), 18–20
sustained low-efficiency dialysis (SLED), 137
SYMPHONY study, 603
syndrome of inappropriate ADH (SIADH), 618, 619, 620, 628, 629, 630
synthetic dialysis membranes, 410
systemic lupus erythematosus (SLE). *See also* lupus nephritis
American College of Rheumatology criteria, 244
membranous nephropathy association, 158, 183
transplantation issues, 540
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), 250
- tacrolimus (Tac)
for CAN prevention, 603
for FSGS, 153
- for idiopathic membranous nephropathy, 162
as immunosuppression maintenance, 592–593, 706–707
for pediatric steroid-resistant nephrotic syndrome, 788
for PVAN, 280
for relapsing nephrotic syndrome, 781
vs. cyclosporine A, 593
- Tatarsall equation, 427
- TBMD. *See* thin glomerular basement membrane disease (TBMD)
- Tenckhoff catheters, 397
- tenofovir, 255, 259–260, 266
- terlipressin, 88, 91–93, **92**
- thiazide diuretics, 219, 619. *See also* hydrochlorothiazide
for calcium stone prevention, 645–646, **645**
hyponatremia association, 621
induction of hyponatremia from, 618, 621
for metabolic acidosis, 615
with NSAIDs, 289
stone reduction, 645–646
vs. ACEi, 218
- thin glomerular basement membrane disease (TBMD), 552–553
- Third National Health and Nutrition Examination Survey (NHANES III), 551
- thrombosis in children, 768–770, **769**
- thrombotic microangiopathies (TMA), 258, 303–304
- thrombotic thrombocytopenic purpura (TTP), 183, 303–304
- tiopronin (α -mercaptopyropionylglycine), 649
- TIPS. *See* transjugular intrahepatic portosystemic shunts (TIPS)
- Toronto Glomerulonephritis Registry, 159
- TRANCEPT observational study, 604
- trandolapril, 34–35, 240
- transient ischemic attack (TIA), as transplantation contraindication, 537
- transjugular intrahepatic portosystemic shunts (TIPS), 88, 92, 93
- transplant glomerulopathy, 599
- triamterene, 127, 645
- TT virus, 454
- tubular atrophy, 172, 177, 186, **295**, 599, 637, 788
- tubulointerstitial nephritis. *See* acute tubulo-interstitial nephritis
- tubulointerstitial nephritis with uveitis syndrome (TINU), 122
- tumor lysis syndrome, 128–132, 634
as cause of crystalline nephropathies, 127
management, 131–132
pathophysiology, 128, 130–131
- 25(OH)-vitamin D deficiency. *See* vitamin D
- type 2 diabetes. *See* diabetes mellitus, type 2
- type IV RTA (hyperkalemic distal RTA), 614
- ultrafiltration (UF)
in cardiac patients, 474
in cardiorenal syndrome, 84
in determination of dialysis time, 423
in diabetes mellitus, 233, 239
dialyzer ultrafiltration coefficient (kUF), 411
failure in peritonitis, 509, 529
mechanics of, 410
- in PD, 407, 479, 482, 485, 488, 490, 490, 500, 502–506
in children, 726, 732, 734
in pediatric hemodialysis, 738–741
in RRT, 141, 471
for therapy-resistant chronic volume overload, 84
- Ultrafiltration Management in Peritoneal Dialysis (ISPD Ad Committee), 490, 504
- Ultrafiltration Versus IV Diuretics for Patients Hospitalized for Acute Decompensated Congestive Heart Failure trial, 84
- unilateral segmental renal hypoplasia, 203
- United Kingdom General Practice Research Database, 288
- United Kingdom Prospective Diabetes Study (UKPDS), 64, 239, 289
- United States Renal Data System (USRDS)
analysis of mortality from PD, 404–405
CKD and race data, 9–10
description, 18–19
Project Database, 19
racial/ethnic group data, 48–49
unremitting nephrotic-range proteinuria, 250
- Untied Network for Organ Sharing (UNOS), 546
- urea kinetic modeling (UKM)
basis/derivation of, 424
goals of, 423
in pediatric hemodialysis, 739
- urea reduction ratio (URR), **416**, **417**, 427–428, 456
- uric acid stones, 647–648
- urinary incontinence, in pediatric patients. *See* pediatric daytime urinary incontinence
- urinary tract infections (UTIs)
in donors, 552, 555
in pediatric patients
acute treatment, 747–749
clinical presentation, 746
diagnosis, 746–747
epidemiology, 747
evaluation/imaging of renal tract, 750
interventions for prevention, 752
pathogenesis, 747
recurrence/recurrence prevention, 747, 748–751
- posttransplantation incidence, 566
- struvite stones from, 647
- in women, 299, 301, 302, 303
- vaccination
for chronic kidney disease, 268
for HBV, 456
for HBV-associated MPGN, 266–267
immunodeficiency and, 441
for pneumococcus, 445
pretransplantation consideration, 539
against *Staphylococcus aureus*, 445
- valdecocix (COX-2), 286
- valsartan, 173–174, 238, 483. *See also* MicroAlbuminuria Reduction with Valsartan (MARVAL) study
- vancomycin, **295**, 444–446
for prevention of PD-associated infections, 512, **513–516**, **517**, **519**, **521**
exit site/tunnel infections, 523
peritonitis, 524, 525
- VA/NIH Acute Renal Failure Trial Network (ATN) study, 141
- varicella-zoster virus, 539, 767, 768

Index

- vascular access for hemodialysis
 - as Achilles heel, 395–396
 - AVF/AVG failure, pharmacological prevention (RCTs), 463–464
 - cuffed CRB prevention (RCTs), 464–465
 - dialysis-related infections, 442–443
 - infections related, 442–443
 - screening/access survival
 - blood flow screening (RCTs), 460–461
 - DU stenosis (RCTs), 461–462
 - other techniques, 462–463
 - vascular access infections, 442–443
 - vascular access planning for hemodialysis
 - evidence for primary AVF, 395–396
 - use of tunneled cuffed cannulas, 396
 - vascular intimal hyperplasia, 599
- Vasodilation in the Management of Acute Congestive Heart Failure trial, 84
- vasopressin, 37, 91, 119, 373–375, 401–403, 415, 734, 736
- ventricular hypertrophy (VH)
 - anemia (in adults) association with, 696
 - ARB therapy for, 316
 - continuous ambulatory PD and, 488
 - home BP as predictor of, 345
 - hypertension and, 433, 474, 480
 - left VH as predictor of CVD in adults, 670
 - monitoring for, 204
 - residual renal function (RRF) and, 480
- verapamil (ndCCB), 238
 - plus trandolapril (VeraTran), 240
 - for slowing progression of kidney disease, 316
- vesicoureteric reflux (VUR), in pediatric patients, 751–753
 - clinical spectrum, 751
 - definition and diagnosis, 751
 - as inherited trait, 751
 - management, 751, 753
 - prognosis, 751
 - screening, 751
- Veterans Administration Health Affairs, 563
- vincristine, 794
- viral infections related to dialysis, 453–454
 - hepatitis B and C, 453–454
 - hepatitis GB virus C, 454
 - hepatitis G virus, 454
 - West Nile Virus, 454
- visceral protein store markers assessment, in hemodialysis patients, 435
- vitamin D
 - antiproteinuric in CKD, 318
 - deficiency for MB and ESRD
 - defined/epidemiology, 356–357
 - 1,25(OH)₂-vitamin D₃, 355, 356, 357, 358
 - outcome determinations, 358–359
 - supplementation for, 357–359
 - 25(OH)-vitamin D deficiency, 357, 359–360
 - deficiency in Itai-Itai disease, 297
 - impaired synthesis in renal osteodystrophy, 685
 - for pediatric renal osteodystrophy, 685
 - placental D₃ conversion, 305
 - relationships with calcium/phosphorus/PTH, 354
 - volume regulation during pregnancy, 300
- warfarin, 178, 179
 - with azathioprine, dipyridamole, steroids, for MPGN, 190–191
 - evaluation for MPGN, 187, 189
 - for HPS, **810**
 - low-dose, for AVG, 463–464
 - for pediatric INS, 769
 - for prevention of AVF/AVG failure, 463, 464
- War Nephritis. *See* acute renal failure (ARF)
- water control/quality issues in dialysis-related infections, 454–455, **454**, 457
- West Nile Virus, 454